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ABSTRACT 
 
Background: Mental illness increases risk for substance use and the presence of substance use 
in people living with mental illness makes diagnosis and treatment of both disorders more 
complicated. For treatment of either disorder to be successful, both must be identified and treated 
individually. The substance use burden and service needs of psychiatric inpatients in Malawi are 
unknown. 
 
Objectives:  The study aimed to determine prevalence of risky substance use and service needs 
among psychiatric inpatients.  
 
Methods: A cross-sectional study was conducted examining subjective substance use using the 
World Health Organization Alcohol, Smoking and Substance Involvement Screening Test 
(ASSIST) version 3.1 in 323 new inpatients aged ≥18 years. The prevalence of risky and lifetime 
substance use was calculated in addition to bivariate analysis and linear regression. The kappa 
statistic was calculated to compare diagnosis of substance use during routine clinical assessment 
on admission with screening using the ASSIST.  
 
Results: ASSIST-linked lifetime prevalence for each substance were alcohol 54.8 %, (95 % CI: 
49.3 - 60.1 %), followed by tobacco 43.7 %, (95 % CI: 38.4 - 49.1 %), and cannabis 39.0 %, (95 
% CI: 33.9 - 44.4 %).  No-one reported any use of amphetamine-type stimulants, hallucinogens, 
or opioids.  The prevalence of moderate risk use, requiring brief intervention were tobacco 19.2 
%, (95 % CI: 15.3 - 23.9 %), cannabis 9.9 %, (95 % CI: 7.1 - 13.7 %), alcohol 7.1 %, (95 % CI: 
4.8 - 10.5 %), sedatives 1.2 %, (95 % CI: 0.4 - 3.3 %) and cocaine 0.6 %, (95 % CI: 0 - 2.4 %).  
High risk use requiring specialist care was identified for alcohol 18.6 %, (95 % CI: 14.7 - 23.2 
%) cannabis 16.7 %, (95 % CI: 13.0 - 21.2 %), tobacco 10.8 %, (95 % CI: 7.9 -14.7 %) and 
inhalants 0.3 %, (95 % CI: -0.1 - 2.0 %).  Interrater agreement for diagnosis of substance use 
disorder between routine clinical assessment compared to ASSIST questionnaire was Kappa = 
0.530 (p < 0.001) which is moderate but statistically significant.  The multivariate linear 
regression to determine the risk factors associated with tobacco, alcohol and cannabis.  Males 
are more likely to use all these substances and have a higher ASSIST score than female patients 
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(p < 0.001).  The model indicated that risky alcohol use is significantly higher in Christians than 
other religions or no religious affiliation (p = .044) while risky cannabis use is significantly 
higher in rural residents compared to urban residents (p = .042). 
 
Conclusions: Results suggest that tobacco, alcohol and cannabis are commonly used among 
psychiatric inpatients in this population. Most patients use substances at risky levels requiring 
both brief intervention and specialist care. Although substance use is common, the detection of 
substance use disorders in admission assessments is moderate and could be improved. The 
ASSIST questionnaire is useful in screening for substance use in psychiatric inpatient 
populations and is likely to improve detection and management.  
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DEFINITIONS OF KEY TERMS 
 
 Appropriate referral letter: designated referral letter or any document with working 
diagnosis made by referring clinician and treatments initiated before referral 
 Clinical Technicians: Paramedics who undergo three years of training with two years of 
theory teaching and one year of clinical teaching and graduate with a diploma in clinical 
medicine. They also undergo a 1-year internship. 
 Comorbidity:  the presence of two or more mental illnesses at the same time. 
 Dual diagnosis: a concurrent diagnosis of both a primary psychiatric disorder and a 
substance use disorder. 
 Medical Assistants: Paramedics who undergo two years of medical training. This is 
made up of one year of theory and one year of clinical attachments and graduate with a 
certificate in clinical medicine.  
 Primary Health Care Clinics: the first level of Malawi Health care delivery system 
(including health centres and health posts).  
 Primary Health Care Workers: Medical Assistants and Clinical Technicians working 
in primary care clinics.  
 Psychiatric Clinical Officers: Paramedics who are initially train as clinical technician 
and undergo additional two years of theory and clinical teaching majoring in mental 
health. They graduate with Bachelor of Science in Clinical Medicine (mental health). 
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Chapter 1.  INTRODUCTION  
 
Substance use remains a significant risk factor for many health problems in general and special 
populations such as psychiatric patients (World Health Organization, 2009). Substance use is 
more prevalent in psychiatric patients and there are many explanations for this effect (Cohen and 
Jacobson, 2001). Despite being prevalent in psychiatric patients, substance use problems are 
often undetected and remain untreated (Cohen and Jacobson 2001). This necessitates a number 
of actions, including the use of improved detection methods, such as valid screening 
questionnaires to detect high-risk patients and the provision of appropriate interventions to 
improve outcomes.  Evidence has shown that there is a significant change in prevalence rates if 
different screening techniques are used to screen for substance use disorders (SUD). Despite 
SUDs being quite prevalent among psychiatric inpatients, few receive interventions for their 
comorbid SUD.  
 
In this quest to address problems resulting from increasing levels of alcohol and drug use across 
the world, the World Health Organization (WHO) (2002) identified alcohol, tobacco and illicit 
drug use as among the top 20 risk factors for ill-health. It has adopted a public health approach 
that includes screening for alcohol and drug abuse as well as provision of early intervention.  
WHO has commissioned several studies to develop reliable and valid screening instruments in 
primary and community health facilities to identify people with both moderate and severe 
substance use problems in general populations. Screening instruments, usually in the form of a 
brief questionnaire, find subjects who have or are at high risk for a disorder in a population of 
interest but do not actually establish a diagnosis (Pilowsky & Wu 2012).  Several screening tools 
have been developed and succeeded one another to reduce the complexity of using them.  
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) questionnaire was 
commissioned because of the successful usage of Alcohol Use Disorder Identification Test 
(AUDIT) in identifying people at risk of developing alcohol use problems (Humeniuk, Henry-
Edwards, Ali, Poznyak & Monteiro, 2010).  Humeniuk et al (2010) further reported that most 
known screening tools were meant for one substance and were time-consuming if used in 
primary health care setting with a large patient load. The ASSIST has been recommended for use 
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in primary health care and other settings as it is a short (8-item) questionnaire which takes a few 
minutes to administer and is able to detect SUDs for 10 psychoactive substances.  
 
Despite the availability of internationally validated cross-cultural screening tools for substances 
such as CAGE and AUDIT for alcohol and ASSIST for all substances of abuse, no substance use 
screening tools are have been validated in, or are currently used in the Malawian health system. 
There is also no systematic, nationally representative data collection on substance use and abuse 
(Braathen, 2008a).  Although substance use services are integrated into mental health services, 
the available data on prevalence of SUDs in psychiatric inpatients are of limited quality.   Bisika, 
Konyani & Chamangwana (2004) conducted a rapid situation assessment on drug abuse and HIV 
at Zomba Mental Hospital (ZMH) in Malawi. The study reported 88.0% of population used 
cannabis and 12.0% used alcohol at least on a monthly basis.  The ZMH medical records, which 
were collected electronically using International Classification of Diseases Tenth Edition (ICD-
10) database between January 2012 and January 2013, recorded an overall prevalence of SUDs 
of 18.5% amongst inpatients.   Mental and behavioural disorders due to use of cannabinoids were 
highest at 8.8%, followed by multiple substances (cannabis and alcohol) at 6.4% and alcohol at 
3.1%. Surprisingly, tobacco use prevalence was very low at 0.1% while clinical experience has 
shown that more patients report using tobacco rather than cannabis and alcohol.  
 
Different diagnostic systems are used by different services.  St. John of God Community 
Services in the north of Malawi runs mental health services which use Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) and ZMH use ICD-10. The peripheral 
centres such as district hospitals which offer secondary care and primary health centres which 
offer primary health care, have no specified screening test and treatment options for SUDs.   
Despite using ICD-10 diagnostic criteria, screening for risky substance use at ZMH is based on 
clinician’s individual discretion. This diversity creates confusion in standards of case 
identification for comorbid or primary SUDs.  .   
 
Pilowsky & Wu (2012) proposed that screening may be useful under the following conditions: 
disorders lead to substantial morbidity; effective treatments are available; treatment is initiated in 
at-risk individuals or in early stages of the disease is more effective than later in the disease 
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course; and disorder is relatively common because it is not cost-effective to screen for disorders 
with low prevalence in the population of interest. These conditions hold for SUD among 
psychiatric inpatients in Malawi: substance use is prevalent among psychiatric patients at ZMH; 
and substance abuse services are available within mental health services (WHO, 2010).  
However, Malawi has a centralized health system and most secondary care hospitals treat few 
psychiatric patients (Kauye, 2008). The unavailability of screening and treatment options at 
secondary care and primary health care levels is a missed opportunity to initiate treatment in at-
risk individuals or in early stages of disease.  
 
Cohen & Jacobson (2001) stated that dual diagnosis of substance use and psychiatric disorder is 
extremely common and often unrecognized. The importance of identifying substance abuse in a 
patient with psychiatric disorder cannot be overstated. In general, patients with dual diagnosis 
have higher morbidity (Curran et al, 2002), lower likelihood for initial treatment success (McKay 
& Weiss, 2001), higher relapse rates, increased rates of hospitalizations, and decreased 
adherence to treatment (Buckley & Brown, 2006). They are also at increased risk for suicide 
(Rosenberg et al, 2005). The presence of substance use disorder in people living with a mental 
disorder makes diagnosis of both disorders more complicated. For treatment of either disorder to 
be successful, both must be identified and treated individually. The use of a valid screening tool 
is important in order to identify patients who have SUDs, whether they are comorbid disorder or 
primary disorders (WHO, 2002; Huang et al., 2009). Since the Malawian health system does not 
have a specific screening tool for SUDs in general practice or in specialist services such as 
mental hospitals, the actual burden of SUDs is not known and substance abuse service needs of 
the population are difficult to estimate.  
 
There are several known studies on substance abuse in Malawi. Peltzer (1989) conducted a 
qualitative study on causative and intervening factors of harmful alcohol consumption and 
cannabis use in general urban population. Carr, Ager, Nyando, Moyo, Titeca, and Wilkinson 
(1994) described characteristics of cannabis (chamba – in Chichewa language) users admitted to 
ZMH.  MacLachlan, Page, Robinson, Nyirenda and Ali (1998) examined the perceptions of the 
social aspects, triggers and effects of cannabis use among psychiatric patients at ZMH. Bisika et 
al (2004) reported on substance abuse and its impact on sexually transmitted diseases, more 
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specifically HIV/AIDS in the general population. Pampel (2005) examined demographic and 
socioeconomic patterns of tobacco use in the general population in Malawi and Zambia in the 
period 2000-2002; Zverev (2008) reported on problem drinking among university of Malawi 
students; Braathen (2008a) reported on substance use and abuse and its implications; and 
Braathen (2008b) explored the relationship of substance use and gender-based violence in the 
general population. However, little is known about the prevalence and factors associated with 
SUDs in Malawi, particularly in psychiatric populations. This study set out to fill this gap by 
investigating prevalence and factors associated with SUDs and service needs at Zomba Mental 
Hospital. 
  
This study was conducted to generate new evidence on the current burden of dual diagnosis or 
comorbid SUDs among psychiatric patients. This should assist in informing the development of 
services which are aimed at addressing individual needs of each patient with psychiatric illness at all 
levels of health care as well as the general public.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Chapter 2.  SYSTEMATIC LITERATURE REVIEW  
1. Background 
 
The United Nations Office on Drugs and Crime (UNODC) (2011) estimated that globally 
between 149 million (3.3 %) and 272 million (6.1 %) people aged 15-64, used illicit substances 
at least once in the previous year. About half of these are estimated to have used illicit drugs at 
least once during the month prior to the survey. This signifies a huge burden of substance use in 
the age group of 15 to 64 years.  
 
Several studies have estimated the prevalence of substance use disorders (SUD) and conducted 
research on the common substances of abuse in general and special population such as 
psychiatric patients.  UNODC (2011) indicated that in all its six regions namely North America; 
South, Central America and Caribbean; Europe; Asia; Oceania; and Africa, the prevalence of 
drug use in the general population is high among all regions but the types of drugs used vary 
across regions. The main problem drugs as indicated by treatment demand of all illicit drug use 
in 2009 were as follows: cannabis contributed significantly to treatment demand in Africa (64%) 
and Oceania (41%); Opioid use in East and South-East Europe, (76%), Asia, (59%), West and 
Central Europe, (47%) and Oceania (32%). In America there was a variation in the substances 
used. Cocaine contributed (50%) treatment demand in South America, while cannabis (28%), 
opioids (25%) and cocaine (27%) were often used in North America.  However, there is a similar 
pattern in terms of common substances of abuse and cannabis is the mostly frequently used drug. 
The global prevalence of illicit drug use among population aged 15-64 was around 5% (range: 
3.4% - 6.2%) in 2009/2010. Despite the high prevalence of illicit substance use, the prevalence 
of problem use (substance use which has led to significant problems in user’s life) is only 0.3% - 
0.9%.  
 
The burden of substance use cannot be overstated and is linked to several risk factors.  Globally, 
studies have indicated that several factors, occurring at the level of individuals, interpersonal 
relations, or society increase the risk for SUDs. Latvala, Tuulio-henriksson, Perälä, Saarni, 
Aalto-setälä, et al (2009) and  Kendler, Prescott, Myers, & Neale (2003) described family history 
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as the strongest risk factor, implicating genetic factors, learned behaviour and availability of 
substances as possible pathways. Young age and male gender have been consistently associated 
with substance use in several studies (Rutter, Ward, Renton, & Rutter, 2001; Weich & Pienaar, 
2009; and Pengpid, Peltzer, & Van der Heever, 2011). Latvala et al (2009) added that low 
education level both of the users and their parents; and having psychiatric comorbidity also 
increase the risk for SUDs.  
 
Globally, concurrent diagnoses of both a primary psychiatric disorder and a SUD (sometimes 
referred to as dual diagnosis) are extremely common and often unrecognized. Approximately 
50% of people diagnosed with SUDs have at least one other psychiatric disorder and conversely, 
almost 30% of patients with other psychiatric disorders also have a history of substance abuse 
(Cohen & Jacobson, 2001). Studies conducted in different parts of the world and using different 
assessment tools have shown different but significant prevalence rates of SUD among psychiatric 
patients. Current (point) prevalence of substance misuse was found to be 24.4% (95% CI: 21.3 -
27.1%) in a cross-sectional study in the United Kingdom among patients with psychotic 
disorders using DSM-IV criteria (Rutter et al., 2001). Bonsack, Camus, Kaufmann, Aubert, 
Besson et al (2006) used routine general interviewing and urine screening among the Swiss 
psychiatric inpatients and found high lifetime substance use disorder prevalence for alcohol 
(98%; 95% CI: 96 - 100%), benzodiazepines (86%; 95% CI: 82 - 91%) and cannabis (53%; 95% 
CI: 47-60 %), cocaine (25%; 95% CI: 19 - 30%) and opiates (20%; 95% CI: 15 - 25%). The 
substances most frequently and currently used were alcohol (32%) and cannabis (17 %). Huang, 
Yu, Chen, Chen, Shen, & Chen (2009) found significant lifetime prevalence of alcohol use 
disorder of 9.8% (alcohol dependence of 8.3%, alcohol abuse 1.5%) in a cross-sectional study in 
Taiwan when they used AUDIT and Structured Clinical Interview for DSM-IV-TR.  
 
In Africa, information on the prevalence of SUD among psychiatric inpatients is limited. 
However, a number of studies have shown similar patterns of substance use among psychiatric 
population. Weich & Pienaar (2009) found a prevalence of 23% for current substance abuse and 
24% for current substance dependence on self-report by acute psychiatric inpatients in Cape 
Town, South Africa. The substances of abuse were cannabis, alcohol, amphetamine/ 
metamphetamine, cocaine/crack cocaine, methaqualone, opioids, benzodiazepines, other 
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stimulants, volatile solvents, ecstasy and hallucinogens. There was a significant increase in the 
overall prevalence when substance use was confirmed by getting more information from relative 
and friends (collateral history). Seventy-nine percent of patients had documented collateral 
substance history and in these cases, dependence was confirmed in 91% and abuse in 82%. 
Overall prevalence of comorbid SUD on self-report and getting more information from relatives 
(collateral history) was as high as 51%.  Analysis of admission to Amanuel Psychiatric hospital 
in Ethiopia revealed 35.4% prevalence of substance abuse, mostly Khat and Alcohol (Fekadu, 
Desta, Alem, & Prince, 2007).  In Zimbabwe, Acuda and Sebit (1997) found the point prevalence 
rate of psychoactive substance abuse among the psychiatric inpatients to be 28.4% (95% CI = 
22.1-34.7%) for alcohol, 27.6% (95% CI = 18.7-36.5%) for tobacco and 14.3% (95% CI = 7.4-
21.2%) for cannabis. This study used a modified World Health Organization AUDIT. This 
suggests that there is a significant change in prevalence if different screening techniques are used 
to screen for SUDs. 
 
To summarise, the high prevalence of substance use among psychiatric inpatients across the 
world is widely acknowledged.  However, there is dearth of documented literature on the 
prevalence of substance use among psychiatric inpatients in Sub-Saharan Africa, and to my 
knowledge a systematic review of literature has not yet been conducted.  Therefore, this 
systematic review was conducted in order to address the gap in our current knowledge.  
 
2. Review Question 
The review question was: what is the prevalence of substance use and what are the possible 
substance abuse service needs in adult psychiatric inpatients on the African continent?   PICOS 
criteria for reporting systematic reviews, refer to participants, interventions, comparisons, 
outcomes and study design (Moher, Liberati, Tetzlaff et al, 2009). In the case of this review, the 
concerned population is adult psychiatric inpatients aged 18 years and above. The issue of 
interest (intervention or indicator) is the prevalence of substance use.  The context (comparator 
or control) is psychiatric hospitals in Sub-Saharan Africa and the outcomes are risky substance 
use (moderate and high risk) and possible substance abuse service needs.  
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3. Search Strategy  
Relevant literature reporting results of the prevalence of substance use among psychiatric 
inpatients and their service needs in Sub-Saharan Africa were identified through search of the 
following databases: Medline – Pubmed; Africa-wide information; Cumulative Index to Nursing 
and Allied Health Literature (CINAHL); PsycINFO; and Psychiatryonline; from January 1990 to 
July 2013 from Sub-Saharan Africa.   The search strategy consisted of four elements (i) 
population (adults aged ≥ 18 years);   (ii) research design of the studies (cross-sectional, cohort, 
and retrospective case reviews); (iii) setting (psychiatric hospitals); and (iv) level of substance 
use (risky, abuse, dependence).  Search terms were used as MESH-headings and as free text 
words (refer to Table 2.1 for details). The search was restricted by excluding comments, letters, 
expert opinions, case reports, and appraisals of randomized control trials or studies of diagnostic 
accuracy of tests.   
 
Table 2.1: PICOS criteria and their corresponding search terms 
PICO Criteria Description of the PICOS criteria Search terms 
P 
Population 
Adult psychiatric inpatients aged 18 years 
and above 
‘psychiatric inpatient*’ OR 
‘psychiatr*inpatient*’ hospitalized OR 
admitted OR ‘mentally-ill inpatient*’  
I Intervention 
or indicator 
Prevalence of substance use Prevalence OR occurrence 
C Context 
(comparator 
or control) 
Psychiatric hospitals in low and middle 
income country  
‘psychiatric hospital’ OR ‘mental hospital’ 
OR ‘psychiatric setting’ OR ‘psychiatric 
institution*’ OR ‘mental asylum*’ AND ‘list 
of all African countries’ 
O 
Outcomes 
Risky substance use (moderate and high 
risk) and substance abuse service needs 
‘substance use’ OR ‘substance abuse’ OR 
‘substance misuse’ OR ‘substance use 
disorder’ OR ‘dual diagnos*’ OR ‘comorbid 
disorder*’ OR ‘drug use’ OR ‘drug abuse’ 
OR ‘psychoactive substance use’ OR 
psychoactive substance misuse’ 
S 
Study design 
Cross-sectional,  cohort, case-and-control  
studies and baseline results of randomized 
control trials  
No search term were specified 
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3.1. Inclusion and exclusion criteria 
Studies were included if: 
 The study utilised a cross-sectional, cohort  design and retrospective case reviews; 
 The study setting was the  Sub-Saharan African country; 
 The study described at least one level of substance use in adults aged 18 years and above; 
 The results mentioned the prevalence of substance use among psychiatric inpatients 
determined by  self-reporting, laboratory testing for specific psychoactive substances, or 
using any reliable screening tool or questionnaire;  
 Study results were written in English or French language either abstract only or full text 
article  or both; 
 The study was published between 1st January 1990 and 31st July 2013. 
 
Studies were excluded if; 
 The subjects were participants in randomised control trials, except the baseline results.  
 The study was not conducted in Sub-Saharan Africa 
 The study was written in language other than French or English 
 
3.2. Abstract and full-text screening 
The researcher (CM) and the supervisor (EB) independently screened research articles for 
eligibility starting with titles and abstracts. When the research article met only two inclusion 
criteria, full-text was accessed to further assess eligibility.  Further full-text article review was 
conducted by the researcher (CM) and King’s College London research expert (RM).  At each 
stage, discussions and agreements on the studies to be included were made.  Additionally, the 
reference lists of all selected articles and published reviews on this topic were screened for 
potentially relevant publications (refer to Figure 2.1 below for a flow chart summarizing the 
whole review process). 
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Figure 2.1: Flow chart of the review process 
3.3. Data extraction 
The researcher independently read all the 24 full-text articles chosen to be included in the 
systematic review.   The predetermined data extraction tool was derived from the components of 
the methodological quality assessment for observational study (Shamliyan, Kane & Dickinson, 
2010).  Fifty-four articles were excluded for the following reasons; 
 13 studies had mixed study population such as psychiatric inpatients and outpatients 
resulting in combined substance use prevalence  
508 records were 
identified 
through database 
search (Box 1) 
378 records remained after duplicates 
were removed 
378 records (abstracts) 
were screened using 
inclusion and exclusion 
criteria (Box 2) 
1 additional record 
was identified 
through other 
sources (Box 1) 
78 full-text articles 
assessed for eligibility 
using inclusion and 
exclusion criteria (Box 2) 
54 of full-text 
articles were 
excluded with 
reasons (see 
data extraction 
section) 
Box 2: Preliminary inclusion and exclusion 
criteria 
Inclusion criteria  
 use of cross-sectional, cohort design and 
retrospective reviews 
 study done in an African country  
 Description of  at least one level of 
substance use  
 population of  adult psychiatric inpatients, 
aged ≥ 18 years and above  
 outcome of substance use determined by  
self-reporting, laboratory testing for 
specific psychoactive substances, or using 
any reliable screening tool or questionnaire  
  English or French language  
 published from 1990 to July 2013 
Exclusion criteria 
 participants for randomised control trials 
 not conducted in Africa 
 written in language other than French or 
English 
 
Box 1: Databases  
Databases of peer-review journal articles 
 Medline – Pubmed 
 Africa-wide information 
 CINAHL;  
 PsycINFO 
 PsycARTICLES 
Other sources 
 Reference lists of all eligible articles  
 Google scholar for relevant 
publications 
24 studies were included in summary of 
prevalence, sample size and other key features of 
the study and assessed the risk of bias (Table 2) 
300 records 
(abstracts) 
were excluded  
Id
entification
 
Screenin
g 
E
ligibility 
In
clu
ded 
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 10  studies used psychiatric outpatients as study population 
 1 study had no specific details of any substance use prevalence 
 10 studies whose full-text articles were difficult to retrieve both electronically and paper-
based copies  
 20 studies with study participants aged ≤ 18 years old 
 
3.4. Methodological quality assessment  
The methodological quality of selected studies was scored by the researcher based on an adapted 
quality criteria list for observational studies.  Shamliyan, Kane & Dickinson, (2010) criteria 
included, (i) nominal components: study design and source for sampling subjects; (ii) 
dimensional component: response rate; and (iii) ordinal judgement component: appropriateness 
of statistical method for given research question.  Table 2.2 presents the extracted data. 
 
4. Data analysis 
The results of the included studies were quantitatively and qualitatively summarized in a table 
format and thereafter a description of the results in a narrative forms and compare and contrast 
them.  Meta-analysis was not done in this review because of the heterogeneity of the studies. 
 
5. Results 
A total of 508 records were identified through the initial database search. After excluding 131 
duplicate records, we retrieved 378 potentially relevant studies. During the title and abstract 
screening 300 of these were excluded because of irrelevant titles and abstracts, and 1 additional 
article was identified as potentially relevant from the references of these studies and relevant 
reviews. 78 full text articles were reviewed by two independent reviewers (CM and RM) and 54 
of these were excluded.  Finally, 24 studies met all inclusion criteria and were included in the 
systematic review (Figure 2.1). The findings from the included studies are summarised in Table 
2.2. 
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Table 2.2: Characteristics and outcomes of included studies 
 
Author & 
Year 
published 
Country 
Sample 
size 
Instrument
(s) used 
Study design 
Source of 
sample 
Inclusion 
criteria 
Design specific sources 
of bias 
Response 
rate 
Statistical method 
 Outcome & Results 
Abayomi et 
al (2013) 
Nigeria 102 
HIV 
screening 
instrument(
HIS), 
AUDIT-C 
Cross-
sectional 
Consecutive 
sampling of 
psychiatric 
inpatients 
Aged ≥18 
years 
No direction of causality, 
convenient sample raises 
possibility of selection 
bias and limit 
generalizability 
97.1% 
Descriptive statistics; 
Chi-square test; Yates' 
Correction 
Prevalence of HIV risk behaviour was 
48 %, majority were males 72.5 %, no 
IV drug use, and alcohol use in past year 
was 40.4 %.  Alcohol was significantly 
related to HIV risk behaviour (P=0.03)  
Adamson et 
al (2010) 
Nigeria 214 
DATER-
questionnai
re (clinical 
assessment 
tool) 
Comparative 
cross-
sectional 
(retrospective
) 
Convenience 
sample of 
psychiatric 
inpatients 
 Aged ≥20 
years 
Use of single sample 
source and convenience 
sample affecting 
generalizability  
100% 
Chi-square, t-test and 
binary regression 
analysis 
 
Prevalence of substance use between 
1992-7 & 2002-7:cannabis, 26.6 %/ 53.3 
% males (91.7%, 90.5%), lowering of 
young age range (30-39, 20-29), 
common substances of abuse, cannabis, 
alcohol and common substances used 
together are cannabis and alcohol 
Atwoli et al 
(2012) 
Kenya 114 
Casenote 
review 
Cross-
sectional 
(retrospective 
and 
prospective) 
Consecutive 
sampling of 
psychiatric 
inpatients 
Aged ≥18 
years 
Use of single sample 
source and convenience 
sample affecting 
generalizability 
100% 
Descriptive statistics; 
Predictive value/ 
sensitivity 
 
Prevalence of substance-related disorder 
at admission (7%) and at discharge 
(12.3%) 
Botha et al 
(2010) 
South 
Africa 
146 
PANSS, 
CAGE 
Comparative 
cross-
sectional 
Convenience 
sample of 
psychiatric 
inpatients 
with 
schizophrenia 
or 
schizoaffectiv
e disorder 
Aged ≥18 
years, with 
schizophren
ia or 
schizoaffect
ive disorder 
 Recall bias affecting the 
data quality 
Not 
applicable 
(N/A) 
Descriptive statistics; 
Chi-square test or 
Fisher's exact test, 
student t test or Mann-
Whitney U test. 
Multivariate analysis 
 
Lifetime use of drugs in High Frequency 
Users, 77.78 %, Low Frequency Users, 
54.05 %; substance use in past 3 months 
in HFU 44.83 %; LFU, 35.71 %.  
Alcohol CAGE HFU, 44.44 %, LFU, 
34.29 %.  Common substances - alcohol, 
cannabis & mandrax for both; 
methamphetamines and heroin in HFU 
only. 
Eze et al 
(2010) 
Nigeria 90 
Semi-
structured 
questionnai
re 
Survey 
Convenience 
sample of 
psychiatric 
inpatients 
Aged 18 
and above 
 Use of unvalidated data 
collection tool, use of 
single centre and 
convenience sample 
affecting generalizability 
89% 
Descriptive statistics; 
Chi-square test or 
Fisher's exact test 
 
 
Common polysubstance use was that of 
alcohol, cannabis and tobacco (52.2%), 
polysubstance use of cocaine, heroin 
and tobacco misuse (2.2%). Cannabis 
alone 35.6%, cocaine alone (2.2%), and 
heroin alone (1.1%)  
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Author & 
Year 
published 
Country 
Sample 
size 
Instrument
(s) used 
Study 
design 
Source of 
sample 
Inclusion 
criteria 
Design specific sources of bias 
respon
se rate 
statistical method 
 Outcome & results 
Frasch 
(2013) 
Nigeria, 
Denmark
, Japan, 
Germany
, 
Switzerla
nd 
2338 (417 - 
Nigeria) 
Clinical 
assessment, 
data review 
Retrospecti
ve 
/prospectiv
e survey 
Consecutive 
sampling of 
psychiatric 
inpatients 
Aged ≥18 
years 
Large differences in sample 
sizes in the study sites; missing 
information for the 
retrospective part 
N/A 
 
Descriptive statistics 
and logistic regression 
 
Overall prevalence was 19%; for 
Nigerian sample was 1.9 %. 82.8% of 
the study participants with SUD (N = 
447, out of 2338) had a lifetime 
diagnosis of harmful alcohol use, 78.5% 
harmful tobacco use, 38.3% harmful use 
of cannabis, 23.5% harmful opioid use, 
36.9%  benzodiazepine use, and 22.8% 
CNS-stimulant drugs use 
Gbiri et al 
(2011) 
Nigeria 102 
Relapse 
Socio-
economic 
Impact 
Interview 
Schedule 
(RSIIS) 
Cross-
sectional 
survey 
Purposive 
sample of 
psychiatric 
inpatients 
Aged ≥18 
years 
Use of single centre and 
purposive sample affecting 
generalizability 
N/A 
Mann-Whitney U-test, 
Multiple regression 
analysis 
 
Prevalence of substance use 25.5%.  
Henning et 
al (2012) 
South 
Africa 
195 
Questionnai
re and 
serological 
tests for 
HIV and 
syphilis 
Sero-
prevalence 
study 
(survey) 
Stratified 
cluster sample 
of psychiatric 
inpatients 
Aged ≥18 
years 
Splicing of cases resulted in 
small sample sizes limiting the 
data analysis  
N/A 
Descriptive statistics; 
Chi-square test, Odds 
Ratio. 
 
21% had cannabis abuse and/ or 
dependence.  5% reported intravenous 
drug use 
Jonsson et 
al (2013) 
South 
Africa 
708 
Casenote 
reviews 
Retrospecti
ve case-
note survey 
Convenience 
sample of 
psychiatric 
inpatients 
 
 
Aged ≥18 
years 
Use of convenience sample and 
data quality in archives 
 N/A 
Descriptive statistics; 
Chi-square test 
   
Prevalence of substance-induced mood/ 
psychotic disorder, 29.8% 
Lund et al 
(2010) 
South 
Africa 
152 
Semi-
structured 
interviews 
and 
questionnai
res 
Retrospecti
ve & 
prospective 
survey 
Consecutive 
sampling of 
psychiatric 
inpatients 
 
 
Aged ≥18 
years 
 Small sample size and 
exclusive to inpatients limiting 
generalizability; exclusion 
criteria based on residence 
leading to biased sample 
characteristics; recall bias on 
retrospective data collection 
 N/A 
Descriptive statistics; 
Chi-square test 
 or Fisher's exact test 
  
Prevalence of comorbid diagnosis of 
substance abuse  50% 
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Author & 
Year 
published 
Country 
Sample 
size 
Instrument
(s) used 
Study 
design 
Source of 
sample 
Inclusion 
criteria 
Design specific sources of 
bias 
Response 
rate 
Statistical method 
 Outcome & Results  
Mamabolo 
(2012) 
South 
Africa 
113 
Structured 
face-to-face 
interviews 
Cross-
sectional 
study 
Systematic 
sample 
randomly 
selected 
psychiatric 
inpatients 
Aged ≥18 
years 
Poor reliability of source of 
information; overlapping 
of sample participants after 
randomization 
 Not 
specified 
Descriptive 
statistics; Chi-square 
test 
  
 13% had substance related disorders. 
Substances used alcohol and unspecified 
drugs with no specific prevalence 
Moosa et al 
(2004) 
South 
Africa 
114 
Questionnai
re   
Cross-
sectional 
study 
Consecutive 
sampling of 
psychiatric 
inpatients 
Aged ≥18 
years 
 No specified limitations  N/A 
Descriptive statistics 
and correlation 
  
60% were abusing unspecified drugs 
Moosa et al 
(2002) 
South 
Africa 
135 
Questionnai
re   
Cross-
sectional 
study 
Consecutive 
sampling of 
psychiatric 
inpatients 
Aged ≥18 
years 
 No specified limitations  N/A 
Descriptive statistics 
  
51% used any substance:, 44% alcohol, 
38% cannabis, 9% benzodiazepines and 
other drugs respectively 
Motala 
(2013) 
South 
Africa 
232 
Record 
review 
Cross-
sectional 
study 
(retrospecti
ve) 
Consecutive 
sampling of 
psychiatric 
inpatients 
Aged ≥18 
years 
One sample source limiting 
generalizability; missing 
data in retrospective 
records; 
 N/A 
Descriptive 
statistics, bivariate 
and multivariate 
analysis 
  
49.5% used substances, 61.06% used 
single substance, and 38.04% used 
multiple substances. Cannabis was used 
by 39.82%; alcohol 15.93% and heroin 
5.31% subjects. Polysubstance 
combination was that of alcohol and 
cannabis which was used by 30.97%. 
Ndetei et al 
(2013) 
Kenya 691 
SCID, 
structured 
interview, 
clinical 
notes 
review 
Cross-
sectional 
comparativ
e study 
Convenience 
sample of 
psychiatric 
inpatients 
Aged ≥18 
years 
Use of unvalidated 
diagnostic/ data collection 
tool and convenience 
sample 
 100% 
Descriptive 
statistics; chi-square 
test: Anova test 
  
 
Alcohol dependence disorders in 
schizophrenia, 14.7%; schizoaffective 
disorder, 28.8%; mood disorders, 
20.8%.  Drug dependence in 
schizophrenia, 10.6%; schizoaffective 
disorder, 17.5%; mood disorders, 
21.6%. 
Niehaus et 
al (2008) 
South 
Africa 
438 
Casenote 
reviews 
Cross-
sectional 
(retrospecti
ve) 
Convenience 
sample of 
psychiatric 
inpatients 
(males only) 
Aged ≥18 
years 
Data quality in archives  N/A 
Descriptive 
statistics; chi-square 
test, cox regression 
38. 9% had comorbid substance-related 
disorder 
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Author & 
Year 
published 
Country 
Sample 
size 
Instrument
(s) used 
Study 
design 
Source of 
sample 
Inclusion 
criteria 
Design specific sources of 
bias 
Response 
rate 
Statistical method 
 
Outcome & results 
Parry et al 
(2002) 
South 
Africa 
1000 
Clinical 
assessment 
using 
DSM-IV 
Descriptive 
epidemiolo
gical study 
(retrospecti
ve) 
Convenience 
sample of 
psychiatric 
inpatients 
Aged ≥21 
years 
Use of convenience sample 
and  data quality in 
archives 
 N/A 
Descriptive statistics 
  
 
Since 1998, alcohol-related discharge 
diagnoses accounted for 5% to 10% in 
all participating psychiatric facilities in 
Gauteng and Cape Town. Diagnoses 
included alcohol related, polysubstance 
use or dual diagnosis.  Between 1997 
and 2000, alcohol-related discharge 
diagnoses accounted for 22% to 27% of 
more than 1000 annual psychiatric 
discharge diagnoses at Stikland Hospital 
in Cape Town 
Parry et al 
(2002) 
South 
Africa 
1000 
Clinical 
assessment 
using 
DSM-IV 
Descriptive 
epidemiolo
gical study 
(retrospecti
ve) 
Convenience 
sample of 
psychiatric 
inpatients 
Aged ≥ 21 
years 
Use of convenience sample 
and  data quality in 
archives 
 N/A 
Descriptive statistics 
  
 
From 1997 to 1999, the 
admission/discharge diagnoses 
accounted for t 5-26% of patients in 
Cape Town, 6-10% of patients in Port 
Elizabeth and 10-16% of patients in 
Gauteng had alcohol-related disorder.  
Cannabis is common illicit drug of use.  
In 1998, 40-60% reported use of 
cannabis in Port Elizabeth  
 
Pillay 
(2011) 
South 
Africa 
732 
Structured 
questionnai
re 
Descriptive 
retrospectiv
e study 
Convenience 
sample of 
psychiatric 
inpatients 
(forensic) 
Aged ≥18 
years 
Use of convenience sample 
and  data quality in 
archives 
N/A 
Descriptive 
statistics; Chi-square 
test 
 
Use of substance prior to committing 
crime, 23.2%; at time of committing 
criminal offence, 49.6%; alcohol 40 %, 
cannabis 33%, others include cocaine, 
mandrax, benzodiazepines, ecstasy, 
glue, heroin, LSD, crack, MDMA, 
rocks. 
Sall et al 
(2009) 
South 
Africa 
38 
Biochemica
l tests, THC 
in urine, 
alcohol 
screening 
Retrospecti
ve cross 
sectional 
study 
Purposive 
sample of 
psychiatric 
inpatients 
(mine 
workers)  
Aged 21 
years 
Use of purposive sample; 
no operationalized research 
variables; small sample 
size to permit statistical 
analysis; potential bias and 
misinterpretation of data to 
desired dataset;  
 N/A 
Descriptive statistics 
  
26% screened positive for pathological 
liver function test GGT and MCV 
indicating recent alcohol use/ abuse as 
well as urine positive test for cannabis 
(THC) 26%. 
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Author & 
Year 
published 
Country 
Sample 
size 
Instrument
(s) used 
Study design 
Source of 
sample 
Inclusion 
criteria 
Design specific sources of bias 
Respons
e rate 
Statistical 
method 
 
Outcome & results 
Strebel et al 
(1999) 
South 
Africa 
7938 
Record 
review 
Retrospective 
epidemiologic
al study 
Random, 
stratified 
sample of 
psychiatric 
inpatients 
Media age 
36.54 years 
Missing data for some eligible cases;   N/A 
Descriptive 
statistics; Chi-
square test , 
Wilcoxon 2-
sample test,  
Substance-related disorders, 32.6%; 
alcohol abuse in female, 6.3%; male, 
15.1%;  other substance abuse, 
female, 3.3% and male, 8.0% 
 
Thuo et al 
(2008) 
Kenya 148 
 
SCID 
DSM-IV 
and SCID 
1-CV 
 
Prospective 
cross 
sectional 
study 
 
Random 
sample of 
psychiatric 
inpatients 
Aged ≥ 18 
years 
 Single data source limiting 
generalizability  
 N/A 
Descriptive 
statistics 
  
30.4% were abusing substances; 
alcohol dependence, 33%; cannabis 
31%; cannabis and alcohol 24%. 
Uys (2013) 
South 
Africa 
19 
Standard 
clinical 
interview 
using 
DSM-IV 
TR criteria 
for 
diagnosis 
Prospective 
survey 
Purposive 
sample of 
psychiatric 
inpatients 
Aged ≥ 26 
years 
Single sex used skewing the results; 
small sample size; use of convenience 
sample; single data source limiting 
generalizability 
12% 
Descriptive 
statistics 
  
No substance abuse, 5% (1) used over 
the counter and prescription 
medications 
Weich et al 
(2009) 
South 
Africa 
298 
Urine test 
for drugs, 
clinical 
assessment 
(patient and 
collateral 
form 
relatives) 
Prospective 
survey 
Convenienc
e sample of 
psychiatric 
inpatients 
Aged ≥ 18 
years 
Use of convenience sample; poor data 
collection format; missing data or 
unreliability of data source (patients) 
 N/A 
Descriptive 
statistics; Chi-
square test, one-
way ANOVA 
and Mann-
Whitney U-test 
  
Self-reported drug use: cannabis 27% 
preferred drug vs 40% used in past 6 
months; alcohol, 23 vs 31%; 
amphetamine/ methamphetamine 13 
vs 20%; cocaine/ crack cocaine 1 vs 
4%; methaqualone 1 vs 9%; opioids 1 
vs 3%; benzodiazepines 2 vs 2%.  
Urine test based drug use: cannabis 
23.8%, methamphetamines 7.4%, 
cocaine 0.7%, Opiates 6.4%, 
methaqualone 5.4%. 
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5.1. Research trends 
There were a number of studies which were conducted in Republic of South Africa, (16, 66.7%); 
then Nigeria, (5, 20.8%); and Kenya, (3, 12.5%).  One study involved multiple countries, in sub-
Saharan, Nigeria and overseas, Germany, Japan, Switzerland and Denmark.  Most studies utilized 
retrospective cross-sectional design and reviews of clinical records.  More than half of the studies 
used non-randomised sampling, convenience (9, 37.5%) and purposive (3, 12.5%).  Only 11 
(45.8%) used random sampling.  It is therefore likely that there was a selection bias of participants 
in the studies.  Out of the 24 included studies, 95.8% were conducted between years 2000 and 
2013, indicating a growing field of research in recent years (see Figure 2.2).  Figure 2.3 shows the 
variation of studies per country of publication. 
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Figure 2.2: Variation of published studies by year 
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Figure 2.3: Variation of published studies by country and year
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In terms of geographical distribution of substances of abuse, South African studies reported a 
range of substances including methamphetamine/ amphetamines, cocaine/ crack cocaine, 
mandrax, heroin, glue, volatile substances, opiates, methaqualone, benzodiazepines, cannabis, 
alcohol and tobacco (Weich & Pienaar, 2009; and Motala, 2013).  Nigerian studies reported more 
cases of cannabis and alcohol and a few cases of heroin and cocaine.  Kenyan studies revealed 
significant use of opioids, alcohol and sedatives/ benzodiazepines and khat.  Khat is a native 
stimulant with a significant cultural importance in eastern Africa, particularly the horn of Africa.   
5.2. Prevalence of substance use 
The studies revealed a great variation in terms of prevalence of substance use.  Some studies 
recorded the overall prevalence ranging from as low as 1.9% (Frasch et al., 2013) and high as 
44.4% in the past 3 months or 77.8% in their lifetime (Botha et al., 2010).  It is not very clear 
though if the diversity of instruments used in the studies changed the prevalence pattern either 
increasing or decreasing it.   The variation in prevalence may have also been influenced by the 
differing definition of substance use in many studies.  The use of psychiatric diagnoses related to 
overall substance use such as abuse and dependence, and targeting specific substance related 
disorders change seem to be the main factors in this variations. The South African studies reported 
marked variations of prevalence of overall substance use. Mamabolo, Magagula, Kruger, Fletcher, 
& Krüger (2012) found prevalence as low as 13%,  while  Lund et al., (2010) reported prevalence 
of 50% based on clinical diagnosis among psychiatric inpatients. The highest prevalence was that 
reported by Botha et al (2010) above.  Another variation was observed in Nigerian studies.  The 
lowest prevalence was that of 1.9% reported by Frasch et al (2013). A significantly higher 
prevalence of 25.5% for all substances was found in recent study examining the socioeconomic 
correlates of relapsed patients in a Nigerian mental hospital (Gbiri, Badru, Ladapo, & Gbiri, 
2011).      
5.3. Prevalence of specific substances of abuse 
Alcohol was commonly used substance with variable prevalence.  Parry et al., (2002) recorded 
alcohol use as low as 5% to 10% in 1998 among people being discharged from psychiatric 
hospitals in Gauteng and Port Elizabeth, South Africa.  In similar study, there was an increase in 
alcohol-related diagnoses on discharge between 1997 and 2000 to range of 22% and 27% of more 
than 1000 annual psychiatric discharge diagnoses at Stikland in Cape Town.  According to this 
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review, the high alcohol prevalence in South Africa was 44% reported by Moosa & Jeenah 
(2002).   In Nigerian psychiatric hospital in Ogun, Abayomi et al., (2013) reported prevalence of 
40.4%. 
 
Cannabis was also common with prevalence ranging from 23.8% as determined by urine test and 
40% on self-reporting in the past 6 months at Stikland Hospital in Cape Town, South Africa 
(Weich & Pienaar, 2009).   Almost similar prevalence, 39.8% was reported at Chris Han 
Baragwanath Academic Hospital psychiatric unit in South Africa (Motala, 2013).  There was 
similar trend in Nigeria and Kenya reporting cannabis prevalence within the range of 20% and 
40%; Adamson, Onifade, & Ogunwale (2010) recorded the lowest in Nigeria, 26.6% and (Thuo, 
Ndetei, Maru, & Kuria, 2008) in Kenya found cannabis prevalence of 31% at Mathari Psychiatric 
Hospital. 
 
Tobacco use was reported in two studies in Nigeria. Eze, Jame, Omoaregba, & Osahon (2010) 
reported that 52.2% of patients used tobacco in combination with cannabis and alcohol use at 
psychiatric hospital in Benin City, Edo state.  But Frasch et al., (2013), in a multinational study 
reported prevalence of 78.5% for the entire study population including Nigeria.  There was no 
specific information on this for Nigeria only.  Prevalence of other substances are highlighted in 
the Table 2.3 below and these include, cocaine, amphetamine like stimulants, benzodiazepines 
and opiates.   There was a reported of abuse of over-the-counter medication as well. 
 
The review has also found polysubstance use among psychiatric inpatients in the sub-Saharan 
region.  The commonest combination of substances is cannabis and alcohol.  Adamson et al., 
(2010) in Nigeria just mentioned the combination but did not highlight the prevalence.  While 
Thuo et al., (2008) in Kenya reported  prevalence of 24.0%.  In South Africa, (Motala, 2013) 
reported a higher prevalence of 30.9%.  According to Eze, Jame, Omoaregba, & Osahon (2010) in 
Nigeria found that the patients were being treated for using three substances; alcohol, cannabis 
and tobacco related problems (52.2%), and cocaine, heroin and tobacco misuse (2.2%). 
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Table 2.3. Summary of studies and their specific substance use prevalence (%) 
Study Country  Instrument(s) Tobacco Alcohol Cannabis Cocaine 
Amphetamine-
type stimulants 
Sedatives  Opioids 
Abayomi et 
al (2013) 
Nigeria 
HIV screening 
instrument(HIS), AUDIT-C 
 40.4%      
Adamson et 
al (2010) 
Nigeria 
DATER-questionnaire (clinical 
assessment tool) 
  26.6%     
Atwoli et al 
(2012) 
Kenya Casenote review         
Botha et al 
(2010) 
South Africa PANSS, CAGE  * *  * mandrax heroin 
Eze et al 
(2010) 
Nigeria Semi-structured questionnaire * * 35.6% 2.2%   1.1% heroin 
Frasch 
(2013) 
Nigeria,  
Clinical assessment, data 
review 
* * * * * * * 
Moosa et al 
(2002) 
South Africa Questionnaire    44% 38%   9%  
Motala 
(2013) 
South Africa Record review  15.93% 
 
39.82% 
 
   5.31% 
Ndetei et al 
(2013) 
Kenya 
SCID, structured interview, 
clinical notes review 
 
In schizophrenia – 
14.7%; schizoaffective 
disorder, 28.8%; Mood 
disorders 20.8% 
     
Parry et al 
(2002) 
South Africa 
Clinical assessment using 
DSM-IV 
 
5 – 10% in 1998; 
22 – 27% , 1997 - 2000 
     
Strebel et al 
(1999) 
South Africa Record review  
Male: 15.1 %; 
Female: 6.3 % 
     
Thuo et al 
(2008) 
Kenya SCID DSM-IV and SCID 1-CV  33% 31%     
Uys (2013) South Africa 
Standard clinical interview 
using DSM-IV TR criteria for 
diagnosis 
      
5% OTC 
prescription 
medicine 
Weich et al 
(2009) 
South Africa 
Urine test for drugs, clinical 
assessment (patient and 
collateral form relatives) 
 
SR –  preferred 23%; 
used past 6 months,  
31%; 
 
SR –  preferred 27%; 
used past 6 months, 
40%;  Urine – 23.8% 
SR –  preferred 1%; 
used past 6 months, 
4%; Urine – 0.7% 
SR –  preferred 
13%; used past 6 
months, 20%; 
Urine – 7.4% 
SR –  preferred 2%; 
used past 6 months, 
2%; Methaqualone SR 
–  preferred 1%; used 
past 6 months, 9%; 
Urine – 5.4% 
SR –  preferred 
1%; used past 6 
months, 3%; 
Urine – 6.4% 
N – Northern Nigeria; S – Southern Nigeria; OTC – over-the-counter; SR - self-reported substance use; *substance was mentioned in the study but no specified prevalence was 
presented; ** the percentage is representing all the substances under the merged row 
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5.4. Instruments used to assess substance use 
There were several instruments which were utilized to assess the level of substance use 
among the included studies in this review. These include: AUDIT-C; CAGE; Standard 
clinical interviews such as the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV TR), Structured Clinical Interview for Diagnostic and 
Statistical DSM Disorders (SCID) or International Classification for Diseases, Tenth Edition 
(ICD-10) classifications; biochemical tests in urine for cannabis and other drugs and blood to 
check liver function test for alcohol use disorder. The rest were assessed using unvalidated 
structured questionnaires developed and administered by the researchers or their assistants. In 
other studies, multiple methods were used such as self-reporting and urine tests.  Fifty percent 
of the studies collected prospective data while 37.5% used retrospective data and 12.5% of 
the studies utilized both prospective and retrospective data. 
 
5.5. Other significant characteristics 
Most of studies reported significant substance use in people between 25 to 35 years old as 
well as male gender.  Females were unlikely to use the commonest psychoactive substance. 
Uys (2013) reported no substance use amongst female psychiatric inpatients with HIV 
infection.  Certain psychiatric disorders were reported in a number of studies as a comorbid 
illness in people using substances.  It was also reported that of those who had comorbid 
substance use disorder 65.0 % had psychotic disorders and  34.0 % had mood disorders 
especially bipolar affective disorder (33.0 %) respectively (Motala, 2013).  Motala (2013) 
further reported that current residence (urban) of the patient was significantly associated with 
substance use.   
6. Discussion 
This systematic review presents the first findings on the prevalence of risky substance use 
among psychiatric inpatients in sub-Saharan region. It reports on the factors associated with 
substance use, and the possible services needs for substance use among this population.  
 
Substance abuse is widespread in psychiatric inpatient populations, although prevalence vary. 
Possible factors include specific patient population factors (including illness, demographic 
and regional factors); measurement factors either screening (validated/ unvalidated) or 
diagnostic instruments; study design and the sampling strategy utilized.  
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Most studies were retrospective in nature increasing risk of bias especially selection and 
attrition biases.  The data were collected in the format which sometimes do not much with the 
desired variable.  The use of self-developed and unvalidated (Motala, 2013)  also increases 
risk of bias. There is greater chance of having more false positives for a condition as the 
researcher can simply manipulate the significant variables to have desired outcomes.  Several 
studies determined prevalence as reported by the participants (Self-reporting).   There is 
potential risk of recall bias.  Self-reporting might either make participants reduce or inflate 
their substance use (Weich & Pienaar, 2009; Cassidy et al (2001) and Sinclair and Latifi 
(2008) in United Kingdom (UK), cited by (Hauli, Ndetei, Jande, & Kabangila, 2011).  
Prevalence either increased or decreased when biological measures such as urine or blood 
samples were used to determine use of other psychoactive substances.  Biomarkers are not 
feasible to detect all substances of abuse depending on their half-life but offers evidence of 
use when refuted on self-reporting in users in urine (Säll, Salamon, Allgulander, & Owe-
Larsson, 2009; Weich & Pienaar, 2009).   Säll et al., (2009) further utilised pathological liver 
function test gamma-glutamyl transpeptidase (GGT) and mean corpuscular volume (MCV) 
indicating recent alcohol use/ abuse. Against this background, it can be concluded that it is 
very important to use multiple methods to ascertain substance use which might be 
underreported or misdiagnosed due to overlap of clinical psychopathology of other 
psychiatric disorders. 
 
There is a trend indicating a growing number of studies over time, indicating a growing 
literature in Africa on substance use and psychiatric disorders, which is encouraging.   
However, the review has highlighted a number of gaps in the available literature in sub-
Saharan Africa.  In terms of research methods, most studies are cross-sectional, and there are 
very few or no longitudinal studies.  Although, cross-sectional studies give good sense of 
prevalence, there were few well designed cross-sectional studies with random sampling.  In 
this case determination of the causal relationship between mental disorders and SUDs and 
generalizability of the findings are limited.  Again, there is a regional variation with most 
studies coming from South Africa, but in most African countries there were no studies. In 
particular, Malawi did not have any study meeting the criteria for this review.   This is an 
opportunity to commission more research studies in the region to determine the regional 
burden and introduce feasible and evidence-based strategies and interventions. 
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The review also revealed skewing of substance use towards certain demographic 
characteristics such as male gender.  This phenomenon is comparable to what Abiodun et al., 
(2013) found in a Nigerian study.  Surprisingly, all patients with alcohol use disorders were 
young aged males.  It seems it is general consensus that males are at a higher risk of 
substance use than females.  Young age is another factor which studies have found to be 
associated with substance use in all populations including mental illness. According to 
Oshodi, Ikeji, Olotu, Ihenyen, & Obianwu, (2009) when examining cannabis use associated-
psychopathology, those using the substance were young (mean age 25.52 ± 5.57.  In the same 
study, males constituted 98.7%.  Mueser et al., (2000) also reported male gender and young 
age as associated factors of substance use.  It is again highlighted that young males are not 
only at risk of substance use in psychiatric population even in primary health care settings 
(Sorsdahl, Stein, Weich, Fourie, & Myers, 2012).   It is imperative that the future studies 
should aim to offer explanations on these phenomenon and develop strategies which are 
gender or age-based or specific to clinical psychiatric diagnoses. Oshodi, Aina, & Onajole 
(2010) recommended revision of health educational programmes targeting the youth when 
high prevalence of substance use was found among them. 
 
This review revealed other associated factors to substance use.  Psychiatric disorders such as 
psychotic, affective (mood) and anxiety disorders were mostly associated with substance 
users.  Grant, Stinson, Dawson, et al. (2004) cited in Pasche (2012) in United States of 
America found that having a SUD increased the risk anxiety disorder by 1.7 to 2.8 times.  
According to Chan,Dennis & Funk (2008) cited in Hall, Degenhardt, & Teesson (2009) 
reported high comorbidity of anxiety, affective and personality disorders.  It is recommended 
that  longitudinal studies should be conducted in order to fully understand the comorbidity of 
substance use and other mental health problems (Hall et al., 2009). 
7. Conclusion 
The review has confirmed the burden of high prevalence of substance use among psychiatric 
inpatients in sub-Saharan region.  Alcohol and cannabis are the most common substances of 
abuse across the region.  Other substances such as khat, heroin, cocaine, methamphetamines, 
mandrax and benzodiazepines are used in specific areas in the region.  This systematic 
review shows a clear gap in our current knowledge on the prevalence and correlates of SUD 
among psychiatric inpatients in Malawi.  
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Chapter 3.  AIM & OBJECTIVES OF STUDY 
1. Aim of the study 
The aim of the study was to determine the prevalence of risky (moderate and high risk) 
substance use and service needs among psychiatric inpatients admitted at ZMH in Malawi 
using the ASSIST questionnaire and compare it with the prevalence identified through 
routine mental health assessment by resident clinicians on admission. 
2. Hypothesis 
It was hypothesized that prevalence of substance use among psychiatric patients is higher 
using the ASSIST than the current 18.5 % being detected by clinicians during routine mental 
health assessment on admission at ZMH (ZMH records) 
3. Objectives 
The study aimed to: 
a) determine the point prevalence of moderate and high risk substance use among 
psychiatric inpatients;  
b) determine the patients’ lifetime prevalence of substance use;  
c) identify the  risk factors associated with substance use;  
d)  assess the extent to which SUDs are detected in routine assessment on admission at 
ZMH; and  
e) determine the proportion of patients suffering from substances use disorders requiring 
services at primary and tertiary levels of care (service needs).  
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Chapter 4. METHODOLOGY 
1. Study design 
This is a quantitative study using a cross-sectional survey design. It was conducted in three 
months, from November 2013 to January 2014. The primary data were collected 
prospectively from patients using structured questionnaires, specifically on socio-
demographic characteristics of the participants and substance use history using the ASSIST 
questionnaire. 
2. Research site 
The study was conducted at ZMH, the only government tertiary psychiatric referral hospital 
in Southern region of Malawi. The hospital offers tertiary services including long-stay care, 
acute in-patient care, out-patient care, hospital day care, forensic services, community 
services, rehabilitation services and occupational therapy. It has a bed capacity of 333 beds 
and it admits 1500 patients annually (Kauye & Mafuta, 2007).  Recent infrastructure 
developments are expected to increase the bed capacity to 400 beds.  There is no-one with 
specialized training in management of substance use disorders in the hospital. The mainstay 
treatment comprises of alcohol detoxification, symptomatic approach targeting the induced 
psychiatric disorders, psychosocial and medical complications plus basic psychoeducation 
and minimally brief intervention for moderate risk users by a psychiatric clinical officer. 
3. Participants 
The population under study comprised of all patients newly admitted for mental healthcare 
services at ZMH during the study period who meet the inclusion criteria.  As a tertiary 
mental hospital, patients are usually referred from other institutions include health centres 
(primary care level) especially in southern region and district hospitals (secondary care level) 
and general tertiary hospitals across the country. Patients are also referred by policy services, 
through the courts. All referred cases are expected to bring with them the appropriate referral 
letter which has at least a working diagnosis.  
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3.1. Procedure  
The procedures followed are shown in Figure 4.1 and described below: 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
Figure 4.1. Flow diagram of study procedure at clinic level 
 
All patients who attended ZMH for 
mental healthcare services 
Assessed for capacity and got 
informed consent then completed 
demographic questionnaire  
Exclusion criteria 
Aged ≤17 years; 
Admitted for other services 
Admitted for inpatient care 
Assess for capacity to consent 
 
Assessed for capacity and got continued informed 
consent then administered ASSIST questionnaire  
Inclusion criteria 
Adults aged ≥ 18 years 
Ability to sustain a meaningful interview 
Admitted for inpatient mental 
healthcare services 
Recruitment process using inclusion 
and exclusion criteria 
Fully awake 
Good capacity to consent 
Able to sustain an interview 
 
 
Non-consenting patients 
 
Excluded from 
study 
Moderate Risk 
Substance use 
Low risk 
Substance use 
High Risk 
Substance use 
Psychoeducation Brief Intervention only (PHC) Brief Intervention + Referral to Specialist (Tertiary) 
Interventions provided by ZMH staff and the researcher  
Eligible participant but drowsy on 
admission – Very disorganized and 
aggressive patients with incoherent 
speech 
Assessed within 72 hours 
 Poor capacity & or refused to consent  
Treated for outpatient care 
 
Mental health assessment 
done by resident clinician 
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3.2. Recruitment 
Following admission to hospital, the research assistant responsible for recruitment and 
administering sociodemographic questionnaires assessed the patients for eligibility for the 
study using the inclusion and exclusion criteria within 72 hours of admission. The patients 
were included if they were adults aged 18 and above, and admitted for inpatient mental 
healthcare services. The patients were excluded if they were admitted for services other than 
mental health services and were disorganized and aggressive in a manner that rendered them 
unable to have a meaningful interview within 72 hours of admission. 
4. Sampling and sample size 
A sample size of 323 patients was calculated for this study. The variables for calculations 
included, acceptable margin of error of 5 %; confidence level set at 95 %; population of 2000 
(the maximum number of patients admitted at ZMH annually); and setting response 
distribution of 50 % as most conservative assumption to give a larger sample with normal 
distribution to make a prediction of the variable in the general population. 
5. Data collection tools 
Data collection was completed using two questionnaires which were translated from original 
English version into Chichewa language.  The first questionnaire was developed by the 
researcher to obtain socio-demographic factors commonly associated with increased risk of 
substance abuse. It included items such as age, level of education, diagnoses written on 
referral letter and diagnoses made by resident clinicians on admission at ZMH. The 
questionnaire had two parts – one was obtained by interview with the patient and the other by 
reading the patient’s file.   
 
The second questionnaire comprised of the 8-item ASSIST questionnaire (version 3.1) 
developed by international experts on addiction for the WHO ASSIST Working Group, 
2002) (appendix 9.6.1). It is designed to be administered to a client using paper and pencil 
and takes about 5 -10 minutes to administer. It is culturally neutral and useable across a 
variety of cultures to screen for use of the following substances: tobacco products, alcohol, 
cannabis, cocaine, amphetamine-type stimulants (ATS), sedatives and sleeping pills 
(benzodiazepines), hallucinogens, inhalants, opioids, and ‘other’ drugs (Humeniuk et al., 
2010). It can be used routinely by a variety of professionals in different settings including 
mental health professionals to assess lifetime prevalence and risk level of substance use. 
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5.1. Translation and Back-translation of data collection tools  
The ASSIST and socio-demographic questionnaires were translated into commonly spoken 
Chichewa language and back translated to English to check whether their meanings were 
preserved. The original English versions of questionnaires were translated into Chichewa by 
native Chichewa speaker and English-taught, qualified Psychiatric Clinical Officer with 
seven years of experience in mental health practice based at ZMH. The translated Chichewa 
versions were then back-translated into English by two Chichewa speaking and English-
taught Psychiatric Clinical Officers with three years’ experience in mental health practice at 
ZMH and more than 5 years as clinical technicians at various hospitals across Malawi. The 
main challenge faced was the names of substances of abuse. Tobacco, alcohol and cannabis 
each have a distinct and widely used one-word Chichewa name. For the rest of the 
substances, there were no specific Chichewa names, hence it was agreed that instead of 
attempting to make names for each category, a common substance in that category was 
mentioned as a prompt to participants. Another issue discussed at length was whether every 
aspect of the ASSIST questionnaire should be translated. The questionnaire has certain areas 
such as the calculation of scores for specific substance involvement. This section is only for 
the one administering the questionnaire not patients. It was therefore resolved that only 
sections which would be used directly by patients should be translated.  These areas include 
the introduction, the questions, and the response card and feedback report card for patients. 
The study’s data collectors were fluent English speakers. Copies of the original and translated 
sociodemographic and ASSIST questionnaires are presented in the appendix section.    
5.2. Sociodemographic Questionnaire   
After recruitment and written informed consent, a research assistant administered the socio-
demographic questionnaire. The patient’s demographic data were verified by cross-checking 
the recorded data in the patient’s file. This was done to ensure high and standard responses, 
due to low literacy of most Malawians (National Statistical Office (NSO) and ICF Macro, 
2011). The additional data captured from the file were diagnoses made by referring clinicians 
and by resident mental health clinicians on admission.  
5.3. ASSIST Questionnaire  
The ASSIST questionnaire was administered orally by another researcher in order to blind 
him or her to the clinicians’ diagnosis. Before administering the ASSIST questionnaire, the 
researcher obtained a verbal consent. All participants who screened positive for moderate 
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and high (risky) substance use were referred for appropriate intervention by the ZMH staff.  
 
6. Data analysis  
Data was analysed using Statistical Package for Social Science, IBM SPSS Statistics version 
22 (www.ibm.com). The analyses were conducted according to their corresponding 
objectives in Table 4.1.  
 
Table 4.1. Data analysis matrix 
Objective  Statistical analysis  
 To describe the clinical and 
sociodemographic characteristics of 
the sample and comparing substance 
users and non-users 
Calculation of proportions for each 
sociodemographic characteristic of the participants 
 To determine the prevalence of 
moderate and high risk substance use 
among psychiatric inpatients  
Calculation of proportions of people with moderate 
and high substance use and their confidence intervals. 
 
 To determine patients’ lifetime 
prevalence of substance use  
Calculation of proportions of people with moderate 
and high substance use and their confidence intervals.  
 
 To identify risk factors associated with 
substance use  
 
 
For bivariate analysis the Pearson Chi-square was used 
for categorical data. Univariate linear regression was 
used to determine variables for multivariate linear 
regression models.  
 
 To assess the extent to which SUDs 
are detected in routine assessment on 
admission at ZMH  
 
Calculation of Interrater agreement on substance use 
diagnosis  using Kappa statistic comparing routine 
clinical assessment of substance use  to ASSIST 
questionnaire 
   
 To determine the proportion of patients 
suffering from substances use disorders 
requiring services at primary and 
tertiary levels of care (service needs)  
Calculation of proportions categorizing cases which 
were supposed to receive primary care intervention 
(brief intervention) and those in need of referral to 
tertiary or specialist hospitals  
 
The prevalence of risky substance use (RSU) for specific substances was calculated by 
summing up the percentages of moderate and high risk substance use.  These two levels were 
chosen because both levels present with biopsychosocial consequences to the users and 
require a form of intervention by skilled personnel.   
 
The following categories or cut-off points were used to describe a participants’ substance use 
and determine service needs 
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a) Risky alcohol use: ASSIST specific substance involvement score of 11 - 26 
(moderate  risk) and 27+ (high risk) 
b) Risky use of all other substances:  ASSIST specific substance involvement score of 4 
– 26 (moderate risk) and 27+ (high risk).   
c) The lifetime prevalence: answering yes to ASSIST questionnaire Q1 for any 
substance in one’s lifetime regardless of risk level 
d) Service needs: based on substance use risk level and corresponding ASSIST-linked 
interventions as outlined in Figure 1 – low risk (no intervention); moderate risk (brief 
intervention at primary health care (PHC) level); and high risk (brief intervention plus 
referral to specialist services at tertiary level) 
 
Table 4.2 presents the cut-off points and interpretations for Kappa statistics as postulated by 
Viera & Garrett (2005). 
  
Table 4.2. Interpretation of kappa statistic (Viera & Garrett, 2005) 
 
            Poor           Slight             Fair                Moderate            Substantial              Almost perfect 
 
Kappa    0.0             .20                .40                   .60                            .80                                 1.0 
Kappa Agreement  
< 0  Less than chance agreement 
0.01–0.20  Slight agreement 
0.21– 0.40  Fair agreement 
0.41–0.60  Moderate agreement 
0.61–0.80  Substantial agreement 
0.81–0.99  Almost perfect agreement 
 
In order to determine the exact socioeconomic status of the research participants, the wealth 
index was used as a background characteristic measuring the long-term standard of living.  
According to the National Statistical Office (NSO) and ICF Macro (2011) this is based on 
data from the household’s ownership of consumer goods; dwelling characteristics; type of 
drinking water source; and other characteristics that are related to individual’s 
socioeconomic status. Gwatkin et al (2000) principles of constructing an index were adapted. 
The principal component analysis generated weight (factor score) (Table 4.3) which were 
later assigned to each asset. 
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Table 4.3 Household assets assigned weights (unique values) from principal component 
analysis 
Household asset(s) Weight (factor score) 
House 0.4767 
Radio 0.4103 
Television 0.2632 
Cellphone 0.5555 
Ground telephone 0.4866 
Refrigerator 0.2565 
Transport means except walking 0.4032 
Safe drinking water source 0.9032 
Electricity 0.6243 
Farming land 0.2860 
Animals for food 0.3647 
 
The procedure was that each participant was assigned a score for each asset.  The scores 
were then summed for each participant. Individuals were ranked according to the total score 
of the items which they possess. The sample was then divided into centiles from one (lowest 
– poor) to two (highest – non-poor). Eventually, a single asset index was developed on the 
basis of data from the entire study sample, and this index is used in the tabulation presented 
(Table 5.2).  
 
The variables that showed significant association in bivariate analysis and univariate linear 
regression were included in multiple linear regression to determine risk factors for specific 
substances commonly used by study population namely tobacco, alcohol and cannabis. 
 
7. Ethical Considerations 
Ethical approval to conduct this study was obtained from Human Ethics Committee at the 
Faculty of Health Sciences, University of Cape Town in Republic of South Africa (HREC 
312/2013) and College of Medicine Research Committee at University of Malawi in Republic 
of Malawi.  Further permission was sought from the Zomba District Health Office to conduct 
the study within Zomba district in Malawi, then the actual study site, ZMH through the 
Director of Mental Health Services and the hospital-based Research and Ethics Committee.  
And finally the permission was sought from the potential participants.   
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All eligible participants were informed of the study procedures and given a participant 
information sheet with consent form (see appendix).  All procedures of getting an informed 
consent were followed and clinical assessments of capacity to consent to the study were done 
twice or thrice. Firstly, the resident mental health clinicians were asked to do a competence 
assessment on patients to consent for the study on admission and wrote an advice sheet to 
research assistants. Secondly, the research assistants did another clinical competence 
assessment and obtained a written informed consent before proceeding with the interviews. 
Thirdly, if the participants were unable to give a meaningful interview within 72 hours of 
admission despite giving written informed consent, another verbal informed consent was 
obtained. This is referred to as continued consent.   Mueller and Instone (2008) indicated that 
continued consent is ideal for research involving participants with mental illness as is the case 
in this study for the following reasons: (a) subject's consent capacity can be expected to 
deteriorate or fluctuate or improve, either due to treatment or progressive or fluctuating 
disorder, during the study, and (b) subjects hold the right to refuse study interventions or to 
revoke their previous consent at any time if they regain or lose the decision capacity. 
 
Confidentiality was maintained at all times. The patients’ names were replaced with unique 
codes for research purpose. The main benefit for the participants was increased knowledge on 
their substance use and those identified by the ASSIST questionnaire to have significant 
substance use risk level were treated accordingly by ZMH staff. The overall risk 
classification of this study was minimal without invasive procedures.   However, exposure to 
a series of interviews during data collection was minimized by rescheduling the interviews if 
participants were tired.   
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Chapter 5.  RESULTS OF THE STUDY  
1. Introduction and sample description 
During the three-month period of data collection, from November 2013 to January 2014, 360 
patients were admitted at the hospital. Out of these 360 patients, 353 were adults aged 18 
years old and above.  All these adults were approached as planned and 29 potential patients 
were excluded because they were severely sick even after 72 hours of admission.  One 
patient declined to take part in the study. Three hundred and twenty-three patients were 
recruited in the study achieving the planned sample size.  
 
2. Socio-demographic and socioeconomic characteristics of the participants 
The age range of the participants was 18 and 70 years; the mean age was 29.6 years with 
standard deviation of 9.2.  The age distribution shows a significant number of users were 
below 45 years (Figure 5.1).  Most of the participants were men (210, 65.0%) and more than 
half (168, 52.0%) had never been married.  In terms of current residence of participants 239 
(74.0 %) were living in a rural area.  The distribution of local tribes of participants was as 
follows: Lomwe (114, 35.3%), Yao (74, 22.9%), Chewa (51, 15.8%) and Ngoni (31, 9.6%).  
The hospital is located in the southern region which is dominated by Lomwe and Yao tribes.  
According to number of years spent on formal education regardless of sex, the majority (182, 
56.3%) had some primary education, and while 117, (36.2%) had secondary education.  
Christians represented 77.4 % of the sample. See Table 5.1 for more details.  
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Figure 5.1: Histogram showing age distribution of the study participants 
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Table 5.1.  Sociodemographic characteristics of participants 
Background characteristic N (%) 
Sex Male 210 (65.0%) 
Female  113 (35.0%) 
Age Mean: 29.6  SD± 9.176  
Local tribe Lomwe 114 (35.3%) 
Yao 74 (22.9%) 
Chewa 51 (15.8%) 
Ngoni 31 (9.6%) 
Mang'anja 18 (5.6%) 
Nyanja 13 (4.0%) 
Sena 8 (2.5%) 
Tumbuka 7 (2.1%) 
Others 7 (2.1%) 
Patient's current residence Rural 239 (74.0%) 
Urban 84 (26.0%) 
Marital status Single 168 (52.0%) 
Married 84 (26.0%) 
Widow/ widower 5 (1.5%) 
Divorced 66 (20.4%) 
Number of years spent on 
formal education 
No formal education 16 (5.0%)  
Primary education 182 (56.3%) 
Secondary education 117 (36.2%) 
Tertiary (university) education 8 (2.5%) 
Patient's employment status Unemployed  216 (66.8%) 
Schooling 22 (6.8%) 
Self-employed 58 (18.0%) 
Employed by organization 24 (7.4%) 
Retired 3 (0.9%) 
Religious affiliation Muslim 70 (21.7%) 
Christian 250 (77.4%) 
Pagan (no religious affiliation) 3 (0.9%) 
 
 
Several variables were considered to determine the socioeconomic status of the participants.  
Fifty-two percent owned a house of any type; 65 (20.1%) have working radio sets and 58 
(18.0%) have a mobile phone.  Two hundred and ninety-nine participants (92.6%) use 
drinking water from protected sources within their neighbourhood. Other variables are 
ownership of land for agricultural use and farm animals for food.  Table 5.2 shows the 
distribution of these socioeconomic variables’ frequencies.  
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Table 5.2. Socioeconomic characteristics of participants 
Socioeconomic characteristic N (%) 
House ownership and type of house  
Did not own house 155(48.0%) 
Stay in rented house with grass thatched roof and mud floor 9 (2.8%) 
Stay in rented house with iron sheet roof and cement floor 23 (7.1%) 
Stay with relative in house with grass thatched roof and mud floor 63 (19.5%)  
Stay with relative in house with iron sheet roof and cement floor 57 (17.6%) 
Stay with relative in house with iron sheet roof and mud floor 2 (0.6%) 
 Homeless 1 (0.3%) 
Owned a house 168 (52.0%) 
 Grass thatched roof and mud floor 100 (31.0%) 
 Iron sheet roof and cement floor 64 (19.8%) 
 Iron sheet and mud floor 4 (1.2%) 
Valuable appliances in patients’ household  
Radio 65 (20.1%) 
Television 15 (4.6%) 
Mobile phone 58 (18.0%) 
Landline phone 5 (1.5%) 
Refrigerator 11 (3.4%) 
Usual means of transport  
On foot 288 (89.2%) 
Bicycle 26 (8.0%) 
Motorcycle/ scooter 1 (0.3%) 
Car 8 (2.5%) 
Usual source of drinking water  
Protected source 299 (92.6%) 
Unprotected source 24 (7.4%) 
Electrification of the house 59 (18.3%) 
Possession of land for agricultural use 165 (51.1%) 
Possession of farm animals for food 109 (33.7%) 
Overall socioeconomic status*  
Poor  189 (58.5%) 
Non-poor 134 (41.5%) 
 
*the categories for overall socioeconomic states derived from centiles calculated from item weights 
(factor scores) after principal component analysis for each item/ variable used to determine 
participants’ socioeconomic status in Table 4.3 
 
3. Clinical characteristics of the participants 
Among referred patients 207 (64.1%) had an appropriate referral letter.  Out of those with 
appropriate referral letters, 30 (14.5%) had a diagnosis of substance use disorder. During 
admission, resident clinicians made presumptive diagnoses according to International 
Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10).  
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Psychotic disorders were the most frequently made diagnosis, (137, 42.4%); followed by 
mood disorders, (91, 28.2%); and mental and behavioural disorders due to psychoactive 
substances (48, 14.9%) (Refer to Table 5.3 below for more details). 
 
Table 5.3: Clinical characteristics on referral letters of participants and diagnoses made on 
admission 
Characteristic N (%) 
Clinical characteristic  
Possession of referral letter 207 (64.1%) 
Previous psychiatric admission 191 (59.1%) 
Substance use diagnosis written on referral letter 30 (14.5%)  
  
Clinical diagnostic group made by ZMH clinicians (ICD-10)  
Psychotic disorder 137 (42.4%) 
Mood disorder 91 (28.2%) 
Substance use disorder 48 (14.9%) 
Epilepsy 17 (5.3%) 
Anxiety disorder 1 (0.3%) 
Other 2 (0.6%) 
No diagnosis 27 (8.4%) 
 
4. ASSIST-linked prevalence of risky substance use 
The overall prevalence of RSU determined by routine clinical assessment was 23.2% (95% 
CI: 18.6 - 28.5%) and 39.0% (95% CI: 33.4 - 44.6%) using the ASSIST.  The overall 
prevalence of RSU for specific substances were as follows; tobacco 30.0% (95% CI: 25.3 - 
35.3%); cannabis 26.6% (95% CI: 22.1 - 31.7%); alcohol25.7% (95% CI: 21.2 - 30.7%). 
Very few used sedatives or sleeping pills, cocaine and inhalants and none used other 
substances.   
 
The prevalence of moderate risk substance use varied between substances with tobacco 
(19.2% (95% CI: 15.3 - 23.9%)), cannabis (9.9% (95 % CI: 7.1 - 13.7%)) and alcohol (7.1% 
(95% CI: 4.8 - 10.5%)) having been used the most.  In terms of the prevalence of high risk 
substance use, the most frequently used substances were alcohol (18.6% (95% CI: 14.7 - 
23.2%)), cannabis (16.7% (95% CI: 13.0 - 21.2%)) and tobacco (10.8% (95% CI: 7.9 - 14.7 
%)).  Only 0.3% (95% CI: -0.1 - 2.0%) used inhalants at high risk level.   For more details 
refer to Table 5.4 below. 
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Polysubstance use was also seen in this study.  Those patients who did use substances 
typically used at least two substances.  The common combination at 14.9% was of tobacco, 
alcohol and cannabis.  Tobacco and alcohol use was at 4.6%.  A small percentage used four 
substances – tobacco, alcohol, cannabis and cocaine, 0.6%. Refer to the Table 5.5 below for 
more details. 
 
Table 5.4: Prevalence of substance use as per risk level and overall RSU with 95% Confidence 
Intervals (n=323) 
Substance of 
abuse 
Low risk level  
% (95% CI) 
Moderate risk level 
% ( 95% CI) 
High risk level % 
(95% CI) 
Overall risky substance use 
prevalence (moderate + high 
risk level) % ( 95% CI) 
Tobacco  
70.0%, 
(CI: 64.5- 74.7%) 
19.2% , 
(CI: 15.3- 23.9%) 
10.8%, 
(CI: 7.9-14.7%) 
30.0% , 
(CI: 25.3- 35.3%) 
Alcohol 
74.3%, 
(CI: 69.3- 78.8%) 
7.1%, 
(CI: 4.8-10.5%) 
18.6%, 
(CI: 14.7-23.2%) 
25.7%, 
(CI: 21.2- 30.7%) 
 
Cannabis 
 
 
73.4%, 
(CI: 68.3-77.9%) 
9.9%, 
(CI: 7.1- 13.7%) 
16.7%, 
(CI: 13.0- 21.2%) 
26.6%, 
(CI: 22.1- 31.7%) 
Cocaine 
99.4%, 
(CI: 97.6- 100%) 
0.6%, 
(CI: 0- 2.4% 
0.0% 
0.6%, 
(CI: 0- 2.4%) 
 
Amphetamine-
type stimulants 
 
100.0% 0.0% 0.0% 0.0% 
Inhalants 
99.7%, 
(CI: 98.0- 100%) 
0.0% 
0.3%, 
(CI: -0.1, 2.0%) 
0.3%, 
(CI: -0.1- 2.0%) 
 
Sedatives or 
sleeping pills 
 
98.8%, 
(CI: 96.7- 99.6%) 
1.2%, 
(CI: 0.4- 3.3%) 
0.0% 
1.2%, 
(CI: 0.4- 3.3%) 
Hallucinogens 100% 0.0% 0.0% 0.0% 
Opioids 100% 0.0% 0.0% 0.0% 
Other – 
specify: 
100% 0.0% 0.0% 0.0% 
ASSIST- determined prevalence of risky 
substance use 
39.0% (CI: 33.4- 44.6%) 
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Table 5.5. Summary of polysubstance use 
Substance use combinations N (%) 
Tobacco, Alcohol and Cannabis 48 (14.9%) 
Tobacco and Alcohol 15 (4.6%) 
Alcohol and Cannabis 3 (0.9%) 
Tobacco and Cannabis 3 (0.9%) 
Tobacco, Alcohol, Cannabis and Cocaine 2 (0.6%) 
Alcohol only 17 (5.3%) 
Tobacco only 9 (2.8%) 
Cannabis only 8 (2.5%) 
No substance used 218 (67.5%) 
Total 323 (100.0%) 
 
5. Lifetime prevalence of substance use 
The lifetime prevalence for specific substances’ use are: alcohol 54.8% (95% CI: 49.3 - 
60.1%); tobacco 43.7% (95 % CI: 38.4 - 49.1%), and cannabis 39.0% (95% CI: 33.9 - 
44.4%). Figure 5.2 shows the lifetime prevalence for specific substances used by inpatients at 
ZMH during the study period.   Psychiatric inpatients at ZMH did not report any use of 
amphetamine-type stimulants, hallucinogens, or opioids neither unusual psychoactive 
substance. 
 
Figure 5.2. Bar chart showing lifetime prevalence of specific substance use among ZMH 
psychiatric inpatients 
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6. Demographic, socioeconomic and clinical characteristics of participants with 
substance use compared with non-users 
Comparing those with risky substance use (RSU) (using any specific substance at either 
moderate or high risk level) to those with low substance use we found that the majority of 
those with RSU were males (94.4%). This is significantly higher than the proportion of males 
in those with low risk substance use (46.2%, χ2 =78.7, p<0.001).  Those with RSU were older 
(M=27.92, SD=7.43) than those with low substance use [M=30.60, SD=10.02); t (314) =2.76, 
p=.006]. However, the magnitude of the differences in the means was very small (eta 
squared=.02). 
 
Residing in the rural area (63.5%) was significantly associated with substance use compared 
to living in an urban area (36.5%, χ2 = 11.84, p = .001).  Psychiatric diagnostic group also 
shown to be significantly associated with RSU at χ2 (1, N=323) = 85.88, p > 001. Education, 
employment, religious affiliation, marital status, previous psychiatric admission and 
possession of appropriate referral letter were distributed similarly across those with and 
without RSU.   Most cases with RSU were diagnosed with psychotic, 38.1% and mood 
disorders, 18.3% and substance use disorders, 36.5%.  Full comparative results are provided 
in Table 5.6.   
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Table 5.6. Comparison of clinical, demographic and socioeconomic characteristics between 
RSU and low risk substance users 
Variable 
Total 
Population 
n=323 
RSU n=126 
Low risk 
substance use 
n=197 
χ2 df t value p-value 
Sex 
Male 210 119 (94.4%) 91 (46.2%) 78.6
6 
1  <.001 
Female 113 7 (5.6%) 106 (53.8%) 
Age 
Mean (±SD) 
29.56y  (±9.18 
y) 
27.92y (±7.43y) 
30.60y 
(±10.02y) 
 314 2.76 .006 
Current residence 
Rural 239 80 (63.5%) 159 (80.7%) 11.8
4 
1  .001 
Urban 84 46 (36.5%) 38 (19.3%) 
Employment status     
Unemployed 216 78 (61.9%) 138 (70.1%) 
8.54
5 
5  .129 
Schooling 22 6 (4.8%) 16 (8.1%) 
Self-employed 58 26 (20.6%) 32 (16.2%) 
Employed somewhere 24 15 (11.9%) 9 (4.6%) 
Retired 3 1 (0.8%) 2 (1.0%) 
Marital status     
Single 168 77 (61.1%) 91 (46.2%) 
9.25
8 
4  .055 
Married 84 26 (20.6%) 58 (29.4%) 
Divorced 66 23 (18.3%) 43 (21.8%) 
Widow 4 0 (0.0%) 4 (2.0%) 
Widower 1 0(0.0%) 1 (0.5%) 
Education attainment     
No formal education 16 8 (6.4%) 8 (4.1%) 
3.03
2 
3  .387 
Primary education 182 64 (50.8%) 118 (59.9%) 
Secondary education 117 50 (39.7%) 67 (34.0%) 
Tertiary education 8 4 (3.2 %) 4 (2.0%) 
Religious affiliation     
Christians 250 102 (81.0%) 148 (75.1%) 
3.69
3 
3  .297 Muslims 70 22 (17.5%) 48 (24.4%) 
Pagan 3 2 (1.6%) 1 (0.5%) 
Socioeconomic status        
Non-poor 134 46 (36.5%) 88 (44.7%) 
2.10
9 
1  .146 
Poor 189 80 (64.5%) 109 (55.3%)     
Previous psychiatric 
admission 
191 81 (64.3%) 110 (55.8%) 2.27 1  .132 
Possession of referral letter 207 85 (67.5%) 122 (61.9%) 1.02 1  .312 
ICD-10 Clinical diagnostic  categories     
Psychotic disorder 137 48 (38.1%) 89 (45.2%) 
85.8
8 
1  <.001 
Mood disorder 91 23 (18.3%) 68 (34.5%) 
SUD 48 46 (36.5%) 2 (1.0%) 
No diagnosis 27 8 (6.3%) 19 (9.6%) 
Other 2 1 (0.8%) 1 (0.5%) 
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7. Risk factors associated with substance use 
Multivariate linear regression analysis was used in order to determine the risk factors 
associated with tobacco, alcohol and cannabis use.  The focus of the analysis were to see 
what clinical and demographic variables were associated with a higher score on the ASSIST. 
One of these was psychiatric diagnosis.  The multivariate linear regressions for all the three 
substances have shown that those with SUD are more likely than those with other psychiatric 
diagnoses to have a higher ASSIST score (p < 0.001). Males are more likely to have higher 
ASSIST scores for all these substances (p < 0.001) and ASSIST scores for alcohol use are 
significantly higher in Christians compared to other religions or no religious affiliation (p = 
.044).  The ASSIST scores for cannabis use are significantly higher in rural residents 
compared to urban residents (p =.042). Several variables were not significant in the models.  
The model showed no significant difference in ASSIST scores between age, current 
employment, residence and tobacco, alcohol or cannabis use.  Current employment and 
socioeconomic status were not significant for alcohol and cannabis.  Level of education was 
also not significant for cannabis.   The prediction models for each of the three substances 
were all significant and accounted for 24.0% variance of ASSIST scores for tobacco use, 
30.3% variance for alcohol use and approximately 32.0% variance for cannabis use 
respectively. The details are elaborated in Tables 5.7 to 5.9. 
 
Table 5.7. Multivariate Linear regression for tobacco use 
ASSIST score for Tobacco use  B 
95% CI for B 
p-value R2 Lower 
bound 
Upper 
bound 
Psychiatric diagnosis (compared to Substance Use 
Disorder) 
.    .240 
Psychotic disorders  -9.628 -13.250 -6.006 <.001 
Anxiety and mood disorders  -11.123 -14.905 -7.342 <.001 
Epilepsy -15.594 -21.414 -9.774 <.001 
Other and no diagnoses  -9.482 -14.369 -4.595 <.001 
Male 5.996 3.534 8.459 <.001 
Age .016 -.109 .141 .802 
Currently employed (compared to unemployed) .106 -2.590 2.802 .939 
 Residing in a rural area -1.138 -3.799 1.522 .401 
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Table 5.8. Multivariate Linear regression for alcohol use 
ASSIST score for Alcohol use B 
95% CI for B 
p-value R2 Lower 
bound 
Upper 
bound 
Psychiatric diagnosis (compared to Substance Use 
Disorder) 
.    .303 
Psychotic disorders  -12.280 -16.342 -8.219 <.001 
Anxiety and mood disorders  -13.500 -17.768 -9.231 <.001 
Epilepsy -19.128 -25.637 -12.618 <.001 
Other and no diagnoses  -11.280 -16.803 -5.758 <.001 
Male 8.214 5.420 11.009 <.001 
Age -.023 -.165 .119 .751 
Residing in a rural area -1.029 -3.990 1.931 .494 
 Christian religion (compared to non-Christian) 3.101 .083 6.119 .044 
Socioeconomic status (rich compared to poor) -.492 -3.135 2.150 .714 
 
 
Table 5.9. Multivariate Linear regression for cannabis use 
ASSIST score for Cannabis use B 
95% CI for B 
p-value R2 Lower 
bound 
Upper 
bound 
Psychiatric diagnosis (compared to Substance Use 
Disorder) 
.    .318 
Psychotic disorders  -14.452 -18.421 -10.483 <.001 
Anxiety and mood disorders  -15.758 -19.902 -11.614 <.001 
Epilepsy -20.139 -26.512 -13.766 <.001 
Other and no diagnoses  -12.702 -18.067 -7.336 <.001 
Male 5.996 3.236 8.756 <.001 
Age -.016 -.155 .122 .818 
Residing in a rural area -3.138 .042 -6.167 -.109 
 Currently employed (compared to unemployed) .231 -2.776 3.239 .880 
 Educated secondary & above (compared to 
primary & below) 
-.663 
-3.414 2.088 
.636 
Socioeconomic status (rich compared to poor) -1.098 -3.712 1.516 .409 
 
 
8. Substance use diagnosis on routine clinical assessment compared to the ASSIST 
In order to assess the extent to which SUDs are detected in routine assessment on admission 
at ZMH compared to ASSIST, the Kappa statistic was used.  The point prevalence of 
substance use determined by routine clinical assessment was 23.2%, (95% CI: 18.6 – 28.5%).  
Table 5.10 shows the details of the kappa statistics for various outcomes.  The overall kappa 
statistic to make a diagnosis of SUD regardless of risk level is found to be Kappa = 0.530 (p 
<.0.001), (95% CI: 0.425-0.627).  This measure of agreement while statistically significant is 
only moderate.   
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Table 5.10. Kappa statistic for routine assessment by resident clinicians at ZMH and ASSIST 
questionnaire  
 SUD made on admission Measurement of agreement  95 % CI 
 Yes No Total Kappa value p-value Lower Upper 
ASSIST        
Positive screen 67 59 126 
.530 <.001 .425 .627 
Negative screen 8 189 197 
Total 75 248 323     
        
Tobacco 
Low 24 202 226 
.341 <.001 .250 .438 
Medium 32 30 62 
High 19 16 35 
Total 75 248 323 
 
Alcohol 
Low 28 212 240 
.258 <.001 .179 .336 
Medium 12 11 23 
High 35 25 60 
Total 75 248 323 
 
Cannabis 
Low 24 213 237 
.281 <.001 .208 .352 
Medium 14 18 32 
High 37 17 54 
Total 75 248 323 
 
9. ASSIST-linked substance use service needs 
Substance use service needs were determined based on the ASSIST-linked interventions to 
corresponding substance use risk level. Patients have moderate risk substance use are offered 
brief intervention at PHC level; and those with high risk use, brief intervention is offered to 
promote change plus referral to specialist services at tertiary level.  Figure 5.3 shows the 
distribution of ASSIST-linked substance service needs of substances ever-used by psychiatric 
inpatients at ZMH.   The patients who screened positive for high risk alcohol (18.6%, (95% 
CI: 14.7 - 23.2%)) and cannabis use (16.7%, (95% CI: 13.0 - 21.2%)) were identified as 
needing tertiary care while tobacco users (19.2%, (95% CI: 15.3 - 23.9%)) required primary 
care services, thus psychoeducation on substances. 
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Figure 5.3. ASSIST-linked substance use service level needs 
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Chapter 6 – DISCUSSION 
1. Overview  
This study presents the first findings on the prevalence of risky substance use among 
psychiatric inpatients in Malawi. It reports on the factors associated with substance use, and 
the needs for services among this population. Finally it reports on the accuracy of clinician 
diagnosis of substance use disorder on admission to ZMH, highlighting the potential missed 
opportunities for detection and treatment of this vulnerable group. 
2. Sociodemographic & clinical characteristics of participants and risk factors for 
substance use  
There are several studies across the world which examined the associated demographic 
profiles of substance users in general population as well as specific population such as 
psychiatric patients.   These variables include age, gender and psychiatric diagnoses just to 
mention a few.  In this study, most substance users were younger with the mean age of 27.92 
years (SD=7.43) than those with low substance use [M=30.60, SD=10.02); t (314) =2.76, p 
=.006].  This finding is similar to many studies conducted among psychiatric inpatients 
(Adamson et al., 2010; Motala, 2013 & Weich & Pienaar, 2009). This is a worrisome 
development considering that the most developing countries like Malawi have a youthful 
population.    
 
According to gender distribution in this study, those reporting RSU were predominantly male 
(94.4%).  The proportion of males is significantly higher than those with low risk substance 
use (46.2%, χ2 =78.7, p < 0.001).   This is in line with the global trend  of a higher 
prevalence of drug use in males (UNODC, 2014).  This phenomenon is similar across the 
sub-Saharan (Acuda & Sebit, 1997; Adamson, Onifade, & Ogunwale, 2010; Motala, 2013;  
Ndetei et al., 2008; & Weich & Pienaar, 2009).  The evidence signifies that substance use 
among female psychiatric inpatients is not common in most sub-Saharan countries.  This 
might be attributed to cultural influence disapproving this behaviour.   
 
RSU for cannabis in this study was dominated by rural residents (63.5%). This was 
significantly associated with substance use compared to living in an urban area (36.5%, χ2 = 
11.84, p = .001) was interesting.  This is against what was reported by UNODC (2012) cited 
in Motala, (2013) stipulating that living in city is associated with increased risk of illicit 
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substance use.  The possible explanation for this is that Malawian population is rural based 
with vast agricultural fields allowing low cost cannabis production with minimal drug law 
enforcing agents’ control.  The study also found that that alcohol and tobacco were not 
associated with residing in a rural area.   It is clear that substance use is prevalent in areas 
where the substance is commonly found.   Cannabis use is equally common in Nigeria among 
psychiatric inpatients (Ohaeri & Odejide, 1993).   
  
Considering the number of years spent on formal education regardless of sex, it was found 
that slightly more than half (56.3%) had some primary education, and while 36.2% had 
secondary education.  The level of education was not associated with substance use  (Motala, 
2013).  Studies continue to highlight that people with psychiatric illness have some form of 
good education (Ndetei et al., 2008 and Mahomed, 2008).  This good level of education 
offers an opportunity for uptake of educational interventions on substance use. 
 
Clinically, the study highlighted that psychotic disorders (38.1%) and mood disorders 
(18.3%) were the main comorbid psychiatric disorders among substance users.  This is 
comparable on higher side to the South African study (Motala, 2013) which reported the 
psychotic disorders (65%) and mood disorders (34%).  Several studies highlighted the 
importance of recognizing high rates of comorbidity of substance use and other psychiatric 
diagnoses (Weich & Pienaar (2009), Rensburg (2007), Ndetei et al., (2008)).  Cohen and 
Jacobson (2001) indicated that dual diagnosis is extremely common and often goes 
undetected.  Cohen and Jacobson (2001) further stipulated that the presence of substance 
abuse makes diagnosis of both disorders more complicated, and for treatment of either disorder 
to be successful, both must be identified and treated individually.  Scientific evidence further 
revealed that comorbid substance use is a significant precipitating factor for psychiatric relapse 
and admission (Botha et al., (2010), Mahomed (2008), and Mzimela (1995)). Unfortunately, this 
study did not examine any effects of substances on the comorbid psychiatric disorders.  
 
As most factors associated with increased risk of substance use have been highlighted in the 
sociodemographic section, this study examined the risk factors using regression models.  The 
multivariate linear regressions models for all the three commonly used substances namely 
tobacco, alcohol and cannabis have shown that those with SUD are more likely than those 
with other psychiatric diagnoses to have a higher ASSIST score (p < 0.001). Males are more 
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likely to have higher ASSIST scores for all these substances (p < 0.001) while that ASSIST 
scores for alcohol use are significantly higher in Christians compared to other religions or no 
religious affiliation (p = .044).  ASSIST scores for cannabis use are significantly higher in 
rural residents compared to urban residents (p =.042).   These findings are similar to the 
clinical and sociodemographic characteristics discussed above.   
3. Prevalence of risky substance use and types of substances 
The study findings have revealed that psychiatric inpatients at Zomba Mental Hospital have 
significant primary or comorbid substance use at all levels of use. The prevalence of 
substance use continued to increase from the recent 18.2% (ZMH records) to 23.2% (95% CI: 
18.6-28.5%) as determined by the routine mental health assessment.  It further increased 
when the ASSIST questionnaire was utilized to screen for risky substance use to 39.0% (95% 
CI: 33.4-44.6%).  The prevalence of substance use among psychiatric inpatients varies 
significantly across the sub-Saharan region.   This study’s ASSIST determined prevalence is 
comparable on higher side to the Kenyan study, (Ndetei et al., 2008) which reported  
prevalence of 34.4%  using SCID questionnaire and clinical notes.   Fifty-one percent of 
inpatients had comorbid SUD in South African study determined by patients’ self-reporting 
(Weich & Pienaar, 2009).  A Tanzanian study reported  a significantly higher prevalence of 
68.5% using the similar ASSIST questionnaire (Hauli et al., 2011).   
 
This study found that alcohol, cannabis and tobacco were common used substances and other 
drugs were minimally or rarely used by the study population.  Acuda & Sebit (1997) reported 
the same substances in Zimbabwe.   However, the results also showed a specified 
geographical distribution pattern of specific substances use among psychiatric inpatients in 
sub-Saharan region; South African studies reported a range of substances including 
methamphetamine/ amphetamines, cocaine/ crack cocaine, mandrax, heroin, glue, volatile 
substances, opiates, methaqualone, benzodiazepines, cannabis, alcohol and tobacco (Weich & 
Pienaar, 2009); Strydom et al, 2011) and Motala, 2013)).  Nigerian studies reported more 
cases of cannabis and alcohol and a few cases of heroin and cocaine.  Kenyan studies (Ndetei, 
Khasakhala, Ongecha, Mutiso, & Kokonya (2007) and Ndetei et al (2008) revealed 
significant use of opioids, alcohol and sedatives/ benzodiazepines and khat.  Khat was also 
reported in  Ethiopian studies (Bimerew, Sonn, & Kortenbout, 2007; & Fekadu et al., 2007).    
The substance thought to be khat was mentioned in comparative retrospective study between 
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Malawi and Scotland on forensic inpatients (Hayward et al., 2010).  Khat is a native stimulant 
with a significant cultural importance in eastern Africa and the horn of Africa.  Its presence in 
Malawi might be as a result of migration of people from Ethiopia and Somalia to South 
Africa.  Despite clinical experience and this study highlighting high nicotine (tobacco) use in 
psychiatric population, low reporting on tobacco within mental health services is not 
surprising as greater emphasis is placed on its effects on physical health rather than 
psychological or mental health.   
4. Lifetime prevalence of substance use  
Alcohol, tobacco and cannabis were the main substances used by the participants in their 
lifetime.  Among those who reported using the substances, the majority were still using them 
during the study period.   Psychiatric inpatients at ZMH did not report any use of 
amphetamine-type stimulants, hallucinogens, or opioids neither unusual psychoactive 
substance.   It might be argued that most people continue to use substances once started with 
only a few stopping on the way.   Cohen and Jacobson (2001) argued that several factors 
including self-medication for psychiatric illnesses can be a possible cause for substance use 
in psychiatric patients. However, this study did not elicit possible reasons for starting and 
continued substance use in this population. 
 
The lifetime prevalence of substance use was not reported in most studies in the sub-Saharan 
region.  However, Cantor-Graae, Nordstro, & Mcneil (2001) reported of lifetime prevalence 
of alcohol of 32.0% as finding for a Zimbabwean study by (Acuda & Sebit, 1997).  In fact the 
study reported the point prevalence rate of psychoactive substance abuse among the 
psychiatric in-patients as follows; alcohol 28.4% (95% CI: 22.1 - 34.7), tobacco 27.6% (95% 
CI: 18.7 - 36.5) and cannabis 14.3% (95% CI: 7.4 -21.2).   Fowler, Carr, Carter, & Lewin, 
(1990)  reported that 59.8% had a lifetime diagnosis of substance abuse or dependence with 
48.4% reporting a lifetime prevalence of alcohol abuse/dependence and 36% cannabis 
abuse/dependence.. Mueser et al. (1990), (1992); Regier et al. (1990); and Lehman et al. 
(1994) cited by Mueser et al., (2000) stipulated that across all studies, alcohol  and cannabis 
were the most common type of substance use disorder. This study found a similar trend.  But 
another remarkable finding was the use of tobacco.  The above studies despite reporting a 
variety of substances left out tobacco use.  Evidence indicates that despite current guidelines, 
mental health professionals rarely address nicotine use among their patients (Olivier et al., 
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2007).  There is need to consider tobacco as a significant substance in psychiatry for the fact 
that it does occur with other substances. 
5. Agreement between routine clinical assessment of substance use and ASSIST 
The study findings have revealed that resident clinicians at ZMH are not routinely picking up 
all risky substance use on admission.  Fifty-nine out of 323 patients screened positive on the 
ASSIST but weren’t diagnosed with a substance use on admission.  There are a number of 
possible explanations to this effect.   First, the public perception that cannabis is the major 
cause of mental illness in Malawi seems to be the same among the health workers even at 
ZMH.  Cannabis is the main substance which is screened.  If the patient reports cannabis use 
the screening for other substances will depend on specific substance use features or pointers 
from the escorting relative or staff of referring hospital.  The hospital recently procured urine 
dipstick for cannabis test – tetrahydrocannabinoid test (THC) to increase it detection.  
Although, the emphasis is on cannabis use, it was surprising to find that around 35 
participants with moderate and high RSU were not diagnosed with SUD.    Second 
explanation is the lack of specific clinical protocols for identifying patients with potential 
substance use problems.  Routinely, mental health assessment involves substance use 
assessment in all patients who are at the age of using substances.  This is not the case for 
ZMH.  Every clinician uses his or her own expertise, therefore those not interested in 
substance use area have limited diagnostic capacity.  The inclusion of the ASSIST in a 
clinical protocol could assist with the identification of RSU. 
 
This study reported that alcohol, tobacco and cannabis are widely used substances among 
psychiatric inpatients at ZMH.  This trend is similar in the clinical practice.  The Malawian 
ministry of health (MoH) has mental health indicators for cannabis and alcohol only leaving 
tobacco as a general health indicator.   Again services are biased towards cannabis induced 
disorders like psychotic disorder not substance use disorders.  These ideologies have lead the 
ZMH clinical team to misdiagnose patients with potential substance use problems.  The 
alcohol users have been wrongly diagnosed as having psychotic disorders like schizophrenia 
when they are presenting with alcohol withdrawal symptoms such as various types of 
hallucinations.   Nicotine withdrawal symptoms from tobacco dependent users is one of the 
main causes of aggressive behaviours in the male acute wards.  Tobacco use is totally banned 
on hospital grounds/in hospital buildings regardless of the level of use.  Although improving 
the identification of substance use on routine admission has been improved lately at the 
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hospital, emphasis has been placed on cannabis only.   The identification of other substances 
used will not only address their service needs but also improve the clinical outcomes of 
patients; reduce the treatment costs (Weich & Pienaar, 2009) and provide valuable 
information for decision-making on substance use issues at hospital, district, regional and 
country levels. 
 
There is potential to improve assessment of SUDs, through the introduction of substance 
routine screening using ASSIST at ZMH.  It will be advantageous for the patients and the 
service by improving the early detection and early treatment for substance use disorders.  The 
possibility of incorporating the ASSIST is high. It has now been translated into Chichewa, 
which is national language it is short, can be administered quickly (3 to 5 minutes) and covers 
9 different substances.  It is easily scored and the score translates directly to the type of 
intervention required. 
   
On the other hand, integration of ASSIST might be challenging.  ZMH has limited qualified 
human resources (Kauye & Mafuta, 2007).  The hospital currently depends on a few 
individuals with no specialist knowledge to deliver the substance use services and the 
organizational culture does not nurture new developments in the long term. Starting the 
ASSIST-linked substance screening and treatment may be relatively easy but it is unlikely to 
be sustainable without policy support at hospital and ministerial level. In addition, various 
strategies to support the screening process could be initiated. There also needs to be enough 
capacity and resources (financial, space, medications) to provide the interventions otherwise 
it will not be sustainable. Firstly, substance use indicators should be developed and made 
clear to health workers. Secondly, a clinical coordinator for substance use screening and 
interventions should be identified and trained properly in order to offer continued mentorship 
on the other health workers.  
 
Substance use service needs 
According to the findings on substance use service needs, brief intervention services will be 
needed by more people using tobacco, 19.2% then almost one tenth (9.9%) of cannabis users 
and 7.1% of alcohol users.  This can be offered by specifically trained health workers, at least 
3 full-time staff on weekly basis (who might need to be hired).  Although, the hospital cater 
mental health services for the whole country, the opportunity to deliver multiple BI sessions 
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is available.  On average, patient hospital stay is 30 to 40 days.  Therefore, the patients will 
have a minimum of 4 sessions before their discharge.  So far, the mainstay treatments for 
substance use disorders are psychoeducation, oral diazepam detoxification for alcohol 
withdrawal syndrome and psychotropic medications for induced disorders such as psychotic 
disorders (antipsychotics) and affective disorders (antidepressants and mood stabilisers). 
 
It was also highlighted that a good number of patients with RSU will require referral to 
specialist services.  BI as a treatment modality has modest effectiveness even in non-
psychiatric primary care patients.  However, this is not a standalone treatment for severe 
cases of substance use disorders such as tobacco and alcohol dependence; patients need 
nicotine replacement therapies (NRTs) and medications to treat addiction.   The existing SUD 
services at ZMH are able to handle alcohol dependence cases only using diazepam.  There is 
limited capacity to handle severe cases of addiction to other substances.  Patients using other 
substances are offered psychoeducation.  ZMH as a public hospital, it does not refer cases to 
private or missionary-run mental health services in Mzuzu city.  However, Saint John of God 
Community Services (SJOG) has residential addiction services for which they charge a fee.  
The service-level agreement which exists between Ministry of Health through ZMH and 
SJOG consists of general adult mental health services for people from five districts in 
northern region of Malawi (http://www.sjog.mw/venegas.html).  ZMH has not yet established 
evidence-based specialist substance use services, but there is an opportunity to start 
developing specialist services.   There are several first degree holders who can pursue master 
degree programmes especially in addiction studies to champion the service development.  
  
6. Study limitations 
Although the findings of this study have indicated that substance use is prevalent in people 
with psychiatric illnesses, several factors limited the reliability of the source of information 
and limiting the estimation of prevalence.  The information was only sought from the patients 
with active mental illness who might have given answers influenced by their 
psychopathology.   Patients might have given desirable answers thinking they might not be 
assisted accordingly if they deny substance use.  In Malawi, the general public always 
attribute mental illness among male patients to use of cannabis.   
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The study was conducted only at ZMH therefore the findings cannot be generalised to the 
entire population of people with mental or psychiatric illnesses.   The cross-sectional design 
utilised in limit the findings to make any causal relationships between substance use and 
other related factors.  In addition, the ASSIST questionnaire has never been validated in 
Malawi.  However, it was validated in Zimbabwe with similar population profile to Malawi. 
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Chapter 7 - CONCLUSION & RECOMMENDATIONS 
1. Conclusion 
The results of this study add to the increasing evidence that substance use disorders is highly 
prevalent in psychiatric inpatients.  It further suggest that tobacco, alcohol and cannabis are 
the commonly used psychoactive substances at ZMH in Malawi.  Among those who use 
substances, a greater percentage of patients use these substances at risky levels requiring both 
primary intervention such as the brief intervention and referral for specialist care. The study 
has also showed that clinicians at ZMH are not routinely diagnosing everyone with substance 
use at a moderate or high risk level.  
 
2. Recommendations 
In the light of the above findings, a number of recommendations have been made for future 
research possibilities, clinical practice and substance abuse policies. 
 
2.1. Future research possibilities 
This study has provided descriptive prevalence data on risky substance use and service needs 
among psychiatric inpatients at ZMH, but further research is needed to address unanswered 
questions. Firstly, there is need to explore the effects of dual diagnosis (having substance use 
disorder and any major psychiatric disorder) on the clinical outcomes of individual patients 
using different combinations of substances.   
 
Secondly, considering the high prevalence rate of risky substance use, it can be hypothesized 
that most patients have multiple biopsychosocial complications secondary to the use of these 
substances, particularly tobacco, alcohol and cannabis.  The most common comorbid 
physical complications include hepatic, gastrointestinal, pulmonary, cardiovascular and 
musculoskeletal.  It would be beneficial to explore the biopsychosocial effects of these 
substances on the users. 
 
Thirdly, international studies have shown that RSU can be managed by brief intervention 
(BI) as primary health care intervention to promote behavioural change in substance use.  
Yet, despite numerous randomized trials on effectiveness of BI on alcohol use, the 
effectiveness and cost effectiveness of intervention has never been demonstrated in Malawi. 
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There is a greater need to have validated interventions with their linked assessment or 
screening tool. Although, studies acknowledge the cross-validation of BI to other substances 
such as cannabis and tobacco, there is need to evaluate the case for Malawi.  The Chichewa 
version of the ASSIST could be validated against a gold standard such as the World Mental 
Health Composite International Diagnostic Interview. 
 
Fourthly, the study again revealed greater use of substances at any stage of one’s life, thus 
the lifetime prevalence. There is need to understand factors for initiation of substance use in 
order to develop preventive strategies.  In particular there is a need to undertake longitudinal 
studies to develop a more advanced understanding of the causal relationship between various 
factors identified in this study and substance abuse. 
 
2.2. Implications for practice 
The agreement on substance use between ASSIST and routine mental health assessment has 
revealed a gap in substance use assessment knowledge and skills.  It is clear that there is need 
to increase the knowledge and improve the clinical skills of resident clinicians at tertiary care 
level in Malawi especially at Zomba Mental Hospital.  ZMH’s clinical department has seven 
clinicians and nursing department having 38 nurses.  These are smaller numbers and feasible 
to train. Experience with other programmes such as HIV care are offered throughout the 
country.  Zomba Mental Hospital is among the hospitals to have all its technical staff as 
certified HIV care providers.  The primary and secondary care levels staff also only managed 
to identify a small percentage of people with substance use problems.  Therefore, it is 
strongly recommended that clinicians at ZMH and in other inpatient and outpatient settings 
in Malawi should have comprehensive training for the identification of SUDS and eventually 
the delivery of evidence-based interventions. It is feasible to train health workers at these 
levels as evidenced by the recent project being piloted in four districts in the Southern region 
and one in Central region.  The project aims at improving the mental health services at 
secondary and primary health care levels.  Synergetic to this programme, substance use 
especially alcohol is regarded as a risk factor for non-communicable diseases (NCDs).   The 
directorate of clinical services in ministry of health in Malawi is already working on 
strategies to address alcohol use.  Existing NCD coordinators can also be responsible for 
substance use screening and interventions could be identified and be trained properly in order 
to offer continued mentorship to other health workers.  
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The ASSIST was used on psychiatric inpatients at ZMH and found to be quick, easy to 
administer and detected more people with RSU. The ASSIST with its linked brief 
intervention could potentially be validated, introduced and standardized for use in Malawi at 
all levels of care to foster behavioural change on substance use. 
 
Apart from utilizing the ASSIST questionnaire coupled with routine mental health 
assessment interview, the detection rate of substance use can be improved by using multiple 
substance use screening or diagnostic tools such as collateral information from relatives and 
significant others and biological assessments (haematological and urinalysis) where feasible 
to identify those at risk of substance use and address their significant related complications.   
 
Since psychiatric illness increases the risk for substance use, there is need to raise clinical 
awareness of comorbid substance use among clinicians and other health workers to intensify 
screening for substance use in all patients.  Comprehensive substance use screening should 
be made mandatory in all people with possible mental health problems at all levels of care as 
part of the integrated clinical care package.   
 
2.3. Implications for policy 
The study has indeed increased the information on the high rates of substance use among 
psychiatric inpatients.  This alone cannot improve the assessment and management 
approaches towards substance use problems among psychiatric patients or general public.  
Substance use disorders should be considered to be among the major risk factor for ill-health.   
The ministry of health (MoH) needs to develop indicators for all substances of abuse which 
can be monitored by all relevant stakeholders.   Information on substance use can be 
incorporated in existing curricula in general and specialized education such as medical 
sciences as well as on-job or in-service training/ continuing professional development 
programme.   The designed and targeted strategies should aim at raising awareness of 
substance use among all relevant stakeholders to prevent, make early diagnosis/ recognition 
and offer early interventions to those at risk of developing these substance-related disorders.   
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APPENDICES 
Appendix 1: UCT ethical approval letter 
 
Chitsanzo Mafuta 
C/o Zomba Mental Hospital 
      P. O. Box 38 
      Zomba 
 
      Email: mftchi002@myuct.ac.za 
      Cell: 00 265 888 343 953 
 
      5th May, 2013 
 
FHS Human Research Ethics Admin Office  
C/o Mrs Lamees Emjedi 
Human Research Ethics Committee 
E 52, Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
Telephone: 27 21 406 6338 
Fax: 27 21 406 6411 
 
Dear Madam, 
 
PREVALENCE OF MODERATE AND HIGH RISK SUBSTANCE USE AND 
SERVICE NEEDS AMONG PSYCHIATRIC INPATIENTS AT ZOMBA MENTAL 
HOSPITAL IN MALAWI 
 
I write to submit the above captioned and attached study protocol for consideration by your 
committee.  
 
I am a Master of Philosophy in Public Mental Health student, student number MFTCHI002 at 
University of Cape Town.   My supervisor, Erica Breuer and Co-supervisor, Associate 
Professor Crick Lund have proofread the protocol and has authorized my protocol submission 
to your committee.  
 
Attached is submission pack with completed protocol application form and all relevant 
documents. 
 
I am looking forward to favourable response. 
 
Yours faithfully,  
 
Chitsanzo Mafuta            Erica Breuer 
Student number: MFTCHI002                   Research Supervisor 
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Appendix 2: COMREC Ethical Approval, University of Malawi  
Chitsanzo Mafuta 
C/o Zomba Mental Hospital 
      P. O. Box 38 
      Zomba 
 
      Email: mftchi002@myuct.ac.za 
       chitsanzomafuta@yahoo.co.uk  
      Cell: 00 265 888 343 953 
 
      5th May 2013 
 
Lucinda Manda-Taylor PhD 
COMREC Administrator  
College of Medicine Research and Ethics Committee 
College of Medicine - University of Malawi 
P/Bag 360 
Chichiri 
Blantyre 3 
Malawi 
Email: mandal@medcol.mw or comrec@medcol.mw 
 
Dear Sir/ Madam, 
 
PREVALENCE OF MODERATE AND HIGH RISK SUBSTANCE USE AND 
SERVICE NEEDS AMONG PSYCHIATRIC INPATIENTS AT ZOMBA MENTAL 
HOSPITAL IN MALAWI 
 
I write to submit the above captioned and attached study protocol for consideration by your 
committee.  
 
I am a Master of Philosophy in Public Mental Health student, student number MFTCHI002 at 
University of Cape Town.   My supervisor, Erica Breuer and Co-supervisor, Associate 
Professor Crick Lund have proofread the protocol and has authorized my protocol submission 
to your committee.  
 
Attached is submission pack with completed protocol application form and all relevant 
documents. 
 
I am looking forward to favourable response.  
 
Yours faithfully,  
 
Chitsanzo Mafuta            Erica Breuer 
Student number: MFTCHI002                   Research Supervisor 
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Appendix 3: ZMH institutional approval letter 
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Appendix 4: Zomba District Health Office approval letter  
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Appendix 5: Participant information sheet and Informed consent form 
Participant Information Leaflet (English Version) 
 
Title of study: Prevalence of moderate and high risk substance use and service needs among 
psychiatric inpatients at Zomba Mental Hospital, Malawi 
 
Principal Investigator:   Chitsanzo Mafuta 
 
Contact Address: 
Zomba Mental Hospital 
P. O. Box 38 
Zomba  
Malawi 
Contact Number: 00 265 888 343 953 
 
Thank you for considering taking part in this research study.  Please take your time to read through 
this participant information sheet concerning the research.   Feel free to ask any questions or concerns 
about this study before consenting taking part.  It is very important that you are satisfied with the 
procedures of this research and what is expected of you as participant.  You must know that taking 
part in this research is voluntary and you have the right to refuse to take part.  Your refusal will not 
jeopardise the kind of care you were supposed to receive at this hospital. 
 
This research has been approved by Human Ethics Committee at the Faculty of Health Sciences, 
University of Cape Town in Republic of South Africa and College of Medicine Research Committee 
at University of Malawi in Republic of Malawi.  Further permission to conduct the research has been 
sought from the Director of Mental Health Services through the hospital-based Research and Ethics 
Committee at Zomba Mental Hospital.  The research will adhere to all necessary guidelines and 
protocols of conducting human research by international community and countries of Malawi and 
South Africa. 
 
 
Information about the research 
 
Study setting:  The research will take place at Zomba Mental Hospital 
 
Aim: To determine the prevalence of moderate and high risk substance use and service needs among 
psychiatric patients admitted at Zomba Mental hospital (Malawi) for mental healthcare services by 
using Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) questionnaire and 
comparing it with routine mental health assessment by resident clinicians on admission. 
 
Procedure: Once you have agreed to take part in the study, you are expected to answer two 
questionnaires. The first questionnaire will be concerning your personal identification information and 
second questionnaire will be concerned with your substance use in your lifetime and past 3 months. 
Potential Participants: This study will recruit all adults aged 18 years and above, who have been 
admitted to the hospital during the study period and are willing to take part in the study.   
 
Benefits of study: The main benefit of this study is your increased knowledge and understanding of 
substance use and the effect of these substances on one’s life.  If you are identified to have substance 
related problems you will receive appropriate treatment or referred to appropriate services 
Risks of study: The overall risk is low as no invasive procedures will be performed.  However, you 
may be tired after completing the interviews. 
 
Privacy and confidentiality: All interviews will be conducted in designated room to ensure privacy.  
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The information gathered about you will be kept in secure place and access will be strictly granted to 
the researcher and all people involved in day to day activities of the study.  However, parts of the 
questionnaire may be shared with ZMH ward staff who may be assisting you in your inpatient 
management. 
 
Taking part in study: Taking part in this study is voluntary.  You can decide either to take part or 
not.  If you consider not take part, your decision will not jeopardise the treatment you were expected 
to receive from this hospital. 
 
Note:   
1. If you have any questions about this study, please call the principal investigator Chitsanzo 
Mafuta on this number 00 265 888 343 953 
2. If you have questions or complaints about this study, please call or write to:        
 
Faculty of Health Sciences, Human Research Ethics Committee  
C/o Mrs Lamees Emjedi 
University of Cape Town  
E 52, Room 24, Old Main Building,  
Groote Schuur Hospital, Observatory 
South Africa 
Telephone: 00 27 21 406 6338  
Fax: 00 27 21 406 6411 
 
Or  
 
Lucinda Manda -Taylor Ph.D 
COMREC Administrator  
College of Medicine Research and Ethics Committee 
College of Medicine - University of Malawi 
P/Bag 360 
Chichiri 
Blantyre 3 
Malawi 
Email: mandal@medcol.mw or comrec@medcol.mw 
Telephone: 00 265 1 877 245 
 
3. You will receive this leaflet to indicate that you have taken part in this study. 
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Participant Information Leaflet (Chichewa Version) 
 
Mutu wakafukufuku: Chiwerengero cha wodwala amene agonekedwa pachipatala cha 
Zomba Mental Hospital ku Malawi chifukwa chogwirirtsa ntchito mankhwala 
ozunguza bongo mopitiliza muyezo (Prevalence of moderate and high risk substance use 
and service needs among psychiatric inpatients at Zomba Mental Hospital, Malawi) 
 
Wamkulu woyang’anira kafukufuku:   Chitsanzo Mafuta 
 
Keyala: 
Zomba Mental Hospital 
P. O. Box 38 
Zomba  
Malawi 
Nambala ya foni: 00 265 888 343 953 
 
Muli wolandilidwa kutenga nawo mbali mukafukufuku uyu.  Chonde tenganoi nthawi kuti 
muwerenge uthenga womwe walembedwa pachikalatachi umene ukufotokoza za 
kafukufukuyu.  Muli omasuka kufunsa amene akuyendetsa kafukufukuyu ngati 
simunamvetse bwino lomwe kuti akulongoselerani mwatsaanetsatane zakafukufuku ameneyu 
musanavomereze kutenga nawo mbali.  Ndichofunika kwambiri kuti mukhale okhutitsidwa 
ndi m’mene kafukufukuyu ayendere  komanso m’mene inu mungatengere nawo mbali.  
Dziwani kuti kutenga nawo mbali ndikosakakamiza ndipo muli ndi ufulu wokana kutenga 
nawo mbali.  Kukana kwanu sikudzabweretsa vuto linalililonse pachithandizo chimene 
munayenera kupatsidwa pachipatala chachikulu cha matenda amisala cha Zomba Mental 
Hospital. 
 
Kafukufukuyu wavomerezedwa ndi Human Ethics Committee yaku University of Cape Town 
ku South Africa komanso ku College of Medicine Research & Ethics Committee yaku 
Malawi.  Kafukufukuyu azatsatira ndondomeko zones zoyenera komanso zololezedwa 
zoyendetsera kafukufuku padziko lonse lapansi komanso m’mayiko a Malawi ndi South 
Africa 
 
Dziwani za kafukufukuyu 
Malo:  Kafukufukufuyu achitikira kuchipatala chachikulu chathandiza matenda amisala cha 
Zomba Mental Hospital ku Zomba 
 
Cholinga: kufufuza uku ndi kwa matenda amene amdza chifukwa chakugwiritsa ntchito 
mankhwala ozunguza bongo komanso kuti chithandizo cha matenda awa chimapezeka 
motani muzipatala m’dziko muno. 
 
Ndondomeko yake: pamene mwavomera kutenga nawo gawo mukafukufukuyu mufunsidwa 
mafunso mizgawo ziwiri.  Mafunso ena akhala okhudzana ndi m’mene mumagwiritsira 
ntchito mankhwala ozunguza bongo kuyambira pamene munabadwa komanso pamiyezi itatu 
yapitayi. 
 
Kutenga nawo mbali: aliyense wodwala amene ali ndi zaka 18 zakubadwa ndikupitilira apo, 
komanso wagonekedwa kuti alandile chithandizo m’chipatala ndiponso ali omasuka 
kutenganowo gawo mosakakamizidwa.  Anthu ofunika ndi 323 
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Ubwino wa kafukufukuyu: ubwino waukulu woonekeratu ndi wakuti anthu amene 
adzatenge nawo mbali  adadziwa bwino lomwe za mankhwala ozunguza bongo m’mene 
angaonongele moyo wa munthu.  Kwa amene adzapezeke ndi vuto ndi mankhwalawa 
adzapatsidwa chithandizo choyenera pa nthawiyo 
 
Vuto la kafukufukuyu: Palibe vuto kwenikweni koma kuti nthawi imene mumaonedwa 
mukabwera kuchipatala izakhala yochulukirapo pang’ono mwina ndikudzakhala wotopa 
chifukwa chofunsidwa mafunso katatu musanagonekedwe. 
 
Chinsinsi:  Zonse zimene mungatiuze zizasungidwa mwachninsi, ndipo zizagwiritsidwa 
mukafukufuku yekhayu.  Dzina lanu silidzalembedwa mulipoti lakafukufukuyu. Omwe 
akupangitsa kafukufukuyu ndi okha ovomerezeka kugwiritsa ntchito zones zomwe 
mungatiuze komanso omwe apereka chilolezo chakafukufukuyu atha kuona ngati njira 
imodzi yowunikira ngati kafukufukuyu akutsatira ndondomeko.  Angakhale chinsinsi 
chidzasungidwa chomwechi, zinthu zina zokhudza mndanda wa mafunso zizaziwitsidwa kwa 
anthu wothandiza wodwala akagonekedwa ku chipatala cha Zomba Mental Hospital. 
 
Choti mudziwe 
1. Ngati muli ndi mafunso ena aliwonse muli omasuka kufunsa mkulu wa kafukufukuyu 
Chitsanzo Mafuta, pa nambala iyi 00 265 888 343 953 
2. Ngati muli ndi mafunso ena aliwonse kapena chidandaulo chokhudza kafukufukuyu 
muli omasuka kuyimbira foni kapena kulemba kalata kwa:  
 
Faculty of Health Sciences, Human Research Ethics Committee  
C/o Mrs Lamees Emjedi 
University of Cape Town  
E 52, Room 24, Old Main Building,  
Groote Schuur Hospital, Observatory 
South Africa 
Telephone: 00 27 21 406 6338  
Fax: 00 27 21 406 6411 
 
Or  
 
Lucinda Manda -Taylor PhD 
COMREC Administrator  
College of Medicine Research and Ethics Committee 
College of Medicine - University of Malawi 
P/Bag 360 
Chichiri 
Blantyre 3 
Malawi 
Email: mandal@medcol.mw or comrec@medcol.mw 
Telephone: 00 265 1 877 245 
 
3. Muzalandira chikalatachi kuti musunge nokha kuti munalowa mukafukufukuyu. 
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Appendix 6: Consent form (English Version) 
 
Statement by the participant: 
 
I.................................................................................................................................................. 
I am consenting to take part in this study after receiving all necessary information about this 
study.  I have understood very well what this research study is all about. 
 
 I know that I have the right to withdrawal from the study any time even without 
giving any proper reason 
 I am freely consenting to take part in this study and I know that all my personal 
information will be kept confidential during and after the study. 
 I know that I am expected to spend at least 20 minutes in total with the research 
assistants and/ researcher 
 I know that I will not be compensated in any form or paid any money for participating 
in this study 
 
Participant’s signature: …………………………………  Date: ………………………… 
If not able to write, use the right thumb fingerprint. 
 
Statement by the interviewer: 
 
I………………………………………………………………………………………………. 
Strongly agree that I have explained all the details of the research, aims, benefits and risks of 
this study to the participant. 
 
Interviewer’s signature: ………………………….....    Date: ……………………………… 
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Consent form (Chichewa Version) 
 
Mau ovomereza kulowa mukafukufuku: 
Ine …………………………………………………………………………………………… 
Ndikuvomereza kuti ndafotokozeredwa momveka bwino ndi kukhutira ndi kafukufukyu 
ndipo ndikuvomera kutenga nawo mbali mukafukufukuyu.  Ndikumvetsa bwino lomwe 
zomwe kafukufukuyu akukhuza. 
 Ndikudziwa kuti ngati ndili ndi maganizo ofuna kusapitiliza kutenga nawo mbali 
mukafukufukuyu, ndingathe kudziwitsa owona zakafukufukuyu ndikundichotsa 
nthawi yomweyo angakhale osawauza chifukwa chenicheni. 
 Ndikuvomereza kutenga nawo mbali makafukufukuyu ndikumvetsetsa kuti nkhani 
zokhudza ine zikasungidwa mwachinsinsi 
 Ndikudziwa kuti ndiyenera kucheza ndi mwini wake kafukufukuyu kapena 
wothandizira kafukufukuyu kwa nthawi yosachepera mphindi makumi awiri  
 Ndikudziwa kuti palibe chipukuta misonzi chinachilichonse kapena malipilo ena 
aliwonse pakutenganowo mbali m’kafukufukuyu  
 
Woyankha mafunso atikitile: ……………………………..  Tsiku: ……………………….. 
Chidindo cha chala chackulu chakumanja (ngati samatha kulemba) 
 
Kuvomereza kwa wofunsa mafunso: 
Ine …………………………………………………………………………………………… 
Ndikutsimikiza kuti ndafotokoza mwatsatanetsatane m’mene kafukufukuyu alili, zofuna zake 
ndi zovuta zina ndi zina kwa olowa mkafukufukuyu. 
 
Wofunsa atikitile: …………………………………………  Tsiku: ………………………. 
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Appendix 7:  Sociodemographic Questionnaire (English Version) 
 
Section A: Research Questions on Sociodemographic data 
 
Patient ID: ……………………Date of Interview: ………………… Time: ……………….. 
Note: When answering the some questions please circle what is applicable to the patient. 
a) Gender: M/ F (circle what is applicable)  
 
b) Age: …………………… 
 
c) Tribe: ………………........    
 
d) Where do you stay? 
1. Rural 
2. Urban 
 
e) Marital Status 
1. Single 
2. Married 
3. Widow/ Widower 
4. Divorced 
 
f) Years of completed education  
1. 0 (no formal education) 
2. 1 – 8 (primary education) 
3. 9 – 12 (secondary education) 
4. 13 and above (tertiary education) 
 
 
 
g) Employment Status  
1. Unemployed and looking for work 
2. Unemployed and not looking for 
work  
3. Schooling 
4. Self-employed 
5. Employed somewhere 
6. Retired  
 
h) Religious affiliation  
1. Muslim 
2. Christian 
3. Pagan 
4. Other
 
i) Do you own a house and what type is it? 
1. No, stay in rented house with grass thatched roof and mud floor 
2. No, stay in rented house with iron sheet roof and cement floor 
3. No, stay with relative in house with grass thatched roof and mud floor 
4. No, stay with relative in house with iron sheet roof and cement floor 
5. Yes, with grass thatched roof and mud floor 
6. Yes, with iron sheet roof and cement floor 
 
j) What kind of valuable household appliances do you have? 
1. Radio 
2. Television set 
3. Mobile phone 
4. Landline phone 
5. Refrigerator 
 
k) What is your usual means of transport? 
1. On foot 
2. Bicycle 
3. Animal driven cart 
4. Motorcycle/scooter 
5. Car 
l) What is your usual source of drinking water?? 
1. Protected source e.g. tap, protected dug well etc.  
2. Unprotected source e.g. river, lake, unprotected dug well, 
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m) Does your house in which you stay in have electricity? 
1. No 
2. Yes 
 
n) Do you own an agricultural land for cultivation? 
1. No 
2. Yes 
 
o) Do you own any farm animals for family consumption or sale? 
1. No 
2. Yes 
 
p) Do you normally have enough food in your house for everyone? 
1. No 
2. Yes 
 
Section B:  Assessment of factors related to diagnoses of Substance Use Disorders or risky 
substance use as recorded in participant’s hospital file (circle what is applicable)  
 
a) Has the patient ever been admitted in any hospital for mental health problem before? 
1. No 
2. Yes 
If yes, how many times and where was she or he admitted? 
…………………………………………………………………………………………………
………………………………………………………………………………… 
 
b) Did the patient come with appropriate referral letter?  
1. No 
2. Yes 
 
c) Is Substance use disorder diagnosis or risky substance use written on referral letter? 
1. No 
2. Yes  
If yes write down exactly what is recorded 
…………………………………………………………………………………………………
………………………………………………………………………………… 
 
d) What diagnosis has been made by the clinician?(write down exactly what is recorded) 
………………………………………………………………………………………… 
 
e) Is substance use disorder diagnosis or risky substance use made by clinician on admission at 
Zomba Mental Hospital? 
1. No 
2. Yes  
If yes write down exactly what is recorded 
.……………………………………………………………………………………… 
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Sociodemographic Questionnaire (Chichewa Version) 
 
Gawo A: Research Questions on Sociodemographic data 
 
Patient ID: …………………… Tsiku: ………………… Nthawi: ……………….. 
(poyankha mafunso otsatirawa, zungulitsani ndi cholembera yankho lomwe likugwirizana ndi zimene 
wodwala wanena)  
a) Ndinu: Mamuna / Mkazi (zungulitsani ndi cholembera yankho lomwe likugwirizana ndi 
zimene wodwala wanena)  
 
b) Zaka akubadwa: ………………….  
 
c) Mtundu wanu: ………………........    
 
d) Kodi mumakhala kuti? 
1. kumudzi 
2. kutauni 
 
e) Ndondomeko yabanja lanu lili bwanji? 
1. Wosakwatira/ wosakwatiwa 
2. Ndili pabanja 
3. Nafedwa 
4. Ukwati unatha/ kulekana 
 
f) Kodi mwakhala pa sukulu kwa zaka 
zingati?  
1. 0 (sindinapiteko kusukulu) 
2. 1 mpaka 8 (pilaimale) 
3. 9 mpaka 12 (sekondale) 
4. 13 ndikupyolera apo (sukulu 
yaukachenjede) 
 
 
g) Kodi mumapanga chiyani 
chokhudzana ndi ntchito pamoyo 
wanu?  
1. Sindili pantchito 
2. Ndili pasukulu 
3. Self-employed 
4. Employed somewhere 
5. Retired  
 
h) Chipembedzo chanu 
1. Muslim 
2. Christian 
3. Pagan 
4. Others 
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i) Kodi mulindi nyumba yanuyanu? Nanga nyumbayo ndiyomangidwa bwanji? 
1. Ayi, ndimakhala ya renti, yofolera ndi udzu, yozila 
2. Ayi, ndimakhala ya renti, yofolera ndi malata, ya simenti pansi 
3. Ayi, ndimakhala ndi achibale, yofolera ndi udzu, yozila 
4. Ayi, ndimakhala ndi achibale, yofolera ndi malata, ya simenti pansi 
5. Eya, yofolera ndi udzu, yozila 
6. Eya, yofolera ndi malata, ya simenti pansi 
 
j) Kodi mulindi katundu wamtengo wapatali wotani m’nyumba mwanu? 
1. Wailesi 
2. Wailesi yakanema 
3. Foni ya m’manja 
4. Foni ya m’nyumba 
5. Filiji 
 
k) Kodi mukafuna kuyenda nthawi zambiri mumayenda bwanji? 
1. Wapansi 
2. Panjinga yakapalasa 
3. Pangolo ya abulu kapena ng’ombe 
4. Panjinga yamoto 
5. Pagalimoto 
 
l) Kodi madzi akumwa mumakatunga kuti? 
1. Pamalo otetezedwa 
2. Pamalo osatetezedwa 
 
m) Kodi m’nyumba imene mumakhala ili ndi magetsi? 
1. Ayi 
2. Eya 
 
n) Kodi mulindi malo anu olimapo? 
1. Ayi 
2. Eya 
 
o) Kodi mulindi ziweto zomwe mungagwiritse ntchito kudya pakhomo panu kapena kugulitsa? 
1. Ayi 
2. Eya 
 
 
Section B:  Assessment of factors related to diagnoses of Substance Use Disorders or risky substance 
use as recorded in participant’s hospital file (circle what is applicable)  
 
a) Has the patient ever been admitted in any hospital for mental health problem before? 
3. No 
4. Yes 
If yes, how many times and where was she or he admitted? 
……………………………………………………………………………………………………… 
 
b) Did the patient come with appropriate referral letter?  
3. No 
4. Yes 
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c) Is Substance use disorder diagnosis or risky substance use written on referral letter? 
3. No 
4. Yes  
If yes write down exactly what is recorded 
………………………………………………………………………………………………………
…………………………………………………………………………… 
 
d) What diagnosis has been made by the clinician? (write down exactly what is recorded) 
………………………………………………………………………………………… 
e) Is substance use disorder diagnosis or risky substance use made by clinician on admission at 
Zomba Mental Hospital? 
3. No 
4. Yes  
If yes write down exactly what is recorded 
.………………………………………………………………………………………………………
……………………………………………………………………………. 
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Appendix 8: WHO – Alcohol, Smoking and Substance Involvement Screening Test (ASSIST 
v3.1) (English Version) 
 
Patient ID: ________________________________ Date: _______________________ 
 
Introduction (please read to client or adapt for local circumstances)* 
The following questions ask about your experience of using alcohol, tobacco products and other drugs 
across your lifetime and in the past three months. These substances can be smoked, swallowed, snorted, 
inhaled or injected (show response card). 
 
Some of the substances listed may be prescribed by a doctor (like amphetamines, sedatives, pain 
medications). For this interview, we will not record medications that are used as prescribed by your 
doctor. However, if you have taken such medications for reasons other than prescription, or taken them 
more frequently or at higher doses than prescribed, please let me know. While we are also interested in 
knowing about your use of various illicit drugs, please be assured that information on such use will be 
treated as strictly confidential. 
 
Before asking questions, give ASSIST response card to client 
QUESTION 1 | In your life, which of the following substances have you ever used (non-medical use 
only)? 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) No Yes 
b. Alcoholic beverages (beer, wine, spirits, etc.) 0 3 
c. Cannabis (marijuana, pot, grass, hash, etc.) 0 3 
d. Cocaine (coke, crack, etc.) 0 3 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 3 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, etc.) 0 3 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 3 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 3 
j. j Other – specify: 0 3 
Probe if all answers are negative: 
“Not even when you were in school?” 
If “No” to all items, stop interview. 
If “Yes” to any of these items, ask Q2 for each substance ever 
used 
 
 
 
QUESTION 2 | In the past three months, how often have you used the 
substances you mentioned (first drug, second drug, etc.)?  
N
ev
er
 
O
nc
e 
or
 
tw
ic
e 
M
on
th
ly
 
W
ee
kl
y 
D
ai
ly
 o
r 
al
m
os
t 
da
ily
 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 2 3 4 6 
b. Alcoholic beverages (beer, wine, spirits, etc.) 0 2 3 4 6 
c. Cannabis (marijuana, pot, grass, hash, etc.) 0 2 3 4 6 
d. Cocaine (coke, crack, etc.) 0 2 3 4 6 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 2 3 4 6 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 2 3 4 6 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.) 
0 2 3 4 6 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 2 3 4 6 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 2 3 4 6 
j. Other – specify: 0 2 3 4 6 
If “Never” to all items in Q2, skip to Q6. 
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If any substances in Q2 were used in the previous three months, continue with Questions 3, 4 & 5 for each substance 
used. 
 
 
 
QUESTION 3 | During the past three months, how often have you had a 
strong desire or urge to use (FIRST DRUG, SECOND DRUG, ETC)?  
N
ev
er
 
O
nc
e 
or
 
tw
ic
e 
M
on
th
ly
 
W
ee
kl
y 
D
ai
ly
 o
r 
al
m
os
t 
da
ily
 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 3 4 5 6 
b. Alcoholic beverages (beer, wine, spirits, etc.) 0 3 4 5 6 
c. Cannabis (marijuana, pot, grass, hash, etc.) 0 3 4 5 6 
d. Cocaine (coke, crack, etc.) 0 3 4 5 6 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 3 4 5 6 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3 4 5 6 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.) 
0 3 4 5 6 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 3 4 5 6 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 3 4 5 6 
j. Other – specify: 0 3 4 5 6 
 
QUESTION 4 | During the past three months, how often has your use of 
(FIRST DRUG, SECOND DRUG, ETC) led to health, social, legal or 
financial problems?  
N
ev
er
 
O
nc
e 
or
 
tw
ic
e 
M
on
th
ly
 
W
ee
kl
y 
D
ai
ly
 o
r 
al
m
os
t 
da
ily
 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 4 5 6 7 
b. Alcoholic beverages (beer, wine, spirits, etc.) 0 4 5 6 7 
c. Cannabis (marijuana, pot, grass, hash, etc.) 0 4 5 6 7 
d. Cocaine (coke, crack, etc.) 0 4 5 6 7 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 4 5 6 7 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 4 5 6 7 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.) 
0 4 5 6 7 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 4 5 6 7 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 4 5 6 7 
j. Other – specify: 0 4 5 6 7 
 
 
QUESTION 5 | During the past three months, how often have you failed 
to do what was normally expected of you because of your use of (FIRST 
DRUG, SECOND DRUG, ETC)? N
ev
er
 
O
nc
e 
or
 
tw
ic
e 
M
on
th
ly
 
W
ee
kl
y 
D
ai
ly
 o
r 
al
m
os
t 
da
ily
 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 5 6 7 8 
b. Alcoholic beverages (beer, wine, spirits, etc.) 0 5 6 7 8 
c. Cannabis (marijuana, pot, grass, hash, etc.) 0 5 6 7 8 
d. Cocaine (coke, crack, etc.) 0 5 6 7 8 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 5 6 7 8 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 5 6 7 8 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.) 
0 5 6 7 8 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 5 6 7 8 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 5 6 7 8 
j. Other – specify: 0 5 6 7 8 
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Ask Questions 6 & 7 for all substances ever used (i.e. those endorsed in Question 1) 
 
QUESTION 6 | Has a friend or relative or anyone else ever expressed 
concern about your use of (FIRST DRUG, SECOND DRUG, ETC.)? 
N
o,
 N
ev
er
 
Y
es
, i
n 
th
e 
pa
st
 3
 
m
on
th
s 
 
N
o,
 in
 t
he
 
pa
st
 3
 
m
on
th
s 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3 
b. Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3 
c. Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3 
d. Cocaine (coke, crack, etc.) 0 6 3 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 6 3 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.) 
0 6 3 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 6 3 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 6 3 
j. Other – specify: 0 6 3 
 
 
QUESTION 7 | Have you ever tried and failed to control, cut down or 
stop using (FIRST DRUG, SECOND DRUG, ETC.)? 
N
o,
 N
ev
er
 
Y
es
, i
n 
th
e 
pa
st
 3
 
m
on
th
s 
 
N
o,
 in
 t
he
 
pa
st
 3
 
m
on
th
s 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3 
b. Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3 
c. Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3 
d. Cocaine (coke, crack, etc.) 0 6 3 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 6 3 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.) 
0 6 3 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 6 3 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 6 3 
j. Other – specify: 0 6 3 
 
 
QUESTION 8 |  
 
N
o,
 N
ev
er
 
Y
es
, i
n 
th
e 
pa
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 3
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Have you ever used any drug by injection? (NON-MEDICAL USE 
ONLY  
 
0 
 
2 
 
1 
 
 
IMPORTANT NOTE: 
Patients who have injected drugs in the last 3 months should be asked about their pattern of injecting during this 
period, to determine their risk levels and the best course of intervention. 
PATTERN OF INJECTING     INTERVENTION GUIDELINES 
 
 
Once weekly or less or 
Fewer than 3 days in a row 
 More than once per week or 
3 or more days in a row 
Further assessment and more intensive 
treatment* 
 
Brief Intervention including “risks 
associated with injecting” card 
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HOW TO CALCULATE A SPECIFIC SUBSTANCE INVOLVEMENT SCORE 
 
For each substance (labelled a. to j.) add up the scores received for questions 2 through 7 inclusive. Do not include the 
results from either Q1 or Q8 in this score. For example, a score for cannabis would be calculated as: Q2c + Q3c + 
Q4c + Q5c + Q6c + Q7c 
 
Note that Q5 for tobacco is not coded, and is calculated as: Q2a + Q3a + Q4a + Q6a + Q7a 
 
THE TYPE OF INTERVENTION IS DETERMINED BY THE PATIENT’S SPECIFIC SUBSTANCE 
INVOLVEMENT SCORE 
 Record specific 
substance score 
No intervention Receive brief 
intervention 
More intensive 
treatment* 
a. Tobacco  0 – 3 4 - 26 
27 + 
 
b. Alcohol  0 – 10 11 - 26 
27 + 
 
c. Cannabis  0 – 3 4 - 26 
27 + 
 
d. Cocaine  0 – 3 4 – 26 
27 + 
 
e. Amphetamine  0 – 3 4 – 26 
27 + 
 
f. Inhalants  0 – 3 4 – 26 
27 + 
 
g. Sedatives  0 – 3 4 – 26 
27 + 
 
h. Hallucinogens  0 – 3 4 – 26 
27 + 
 
i. Opioids  0 – 3 4 – 26 
27 + 
 
j. Other drugs  0 – 3 4 - 26 
27 + 
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WHO ASSIST V3.0 RESPONSE CARD FOR PATIENTS 
Response Card – Substances 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 
 
b. Alcoholic beverages (beer, wine, spirits, etc.) 
 
c. Cannabis (marijuana, pot, grass, hash, etc.) 
 
d. Cocaine (coke, crack, etc.) 
 
e. Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 
 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 
 
g. Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, etc.) 
 
h. Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 
 
i. Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 
 
j. Other – specify: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Response Card (ASSIST Questions 2 – 5) 
Never: not used in the last 3 months 
Once or twice: 1 to 2 times in the last 3 months. 
Monthly: 1 to 3 times in one month. 
Weekly: 1 to 4 times per week. 
Daily or almost daily: 5 to 7 days per week. 
 
Response Card (ASSIST Questions 6 to 8) 
No, Never 
Yes, but not in the past 3 months 
Yes, in the past 3 months 
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ALCOHOL, SMOKING AND SUBSTANCE INVOLVEMENT SCREENING TEST (WHO ASSIST 
V3.1) FEEDBACK REPORT CARD FOR PATIENTS 
 
Name________________________________ Test Date _____________________ 
 
Specific Substance Involvement Score 
Substance Score           Risk level 
a. Tobacco products (cigarettes, chewing tobacco, cigars, 
etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
b. Alcoholic beverages (beer, wine, spirits, etc.) 
 
 0-10          Low 
11-26        Moderate 
27+           High 
c. Cannabis (marijuana, pot, grass, hash, etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
d. Cocaine (coke, crack, etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
e. Amphetamine-type stimulants (speed, meth, ecstasy, 
etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
g. Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
h. Hallucinogens (LSD, acid, mushrooms, trips, 
ketamine, etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
i. Opioids (heroin, morphine, methadone, 
buprenorphine, codeine, etc.) 
 
 0-3            Low 
4-26         Moderate 
27+           High 
j. Other – specify: 
 
 0-3            Low 
4-26         Moderate 
27+           High 
 
 
 
 
 
 
 
 
 
What do your scores mean? 
 
Low: You are at low risk of health and other problems from your current pattern of use. 
 
Moderate: You are at risk of health and other problems from your current pattern of 
substance use. 
 
High: You are at high risk of experiencing severe problems (health, social, financial, 
legal, relationship) as a result of your current pattern of use and are likely to be dependent 
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WHO – ASSIST V3.1 Chichewa Version 
 
Nambala ya wodwala:________________________ Tsiku: _______________________ 
 
Mau oyamba (chonde m’muwerengere wodwala izi) 
Zikomo posankha kutenga nawo mbali kuti mufunsidwe mafunso wokhuzana ndi nkhani za mowa, fodya ndi 
mankhwala osiyanasiyana ozunguza bongo.  Ndikufunsani mafunso ammene mwakhala mukugwiritsira ntchito 
mankhwala ozunguza bongo amenewa m’moyo wanu wonse komanso pamiyezi itatu yapitayi.  Mankhwala ozunguza 
bongowa anga gwiritsidwe ntchito posuta, pakuwameza, kufwekheza, kupumidwa mufweya, kuchita kuperekedwa 
munjira ya kubayidwa jakisoni, kapena ngati mapilitsi. 
 
Ena mwamankhwalawa angathe kukhale mankhwala woti adokotala akupatsani kuchipatala monga mankhwala 
wochepetsa ululu, wothandiza kuti munthu agone).  Mafunso amene ndikufunseniwa sakhudzana ndi mankhwala 
amene mwachita kulemberedwe ndi adokotala anu.  Koma ngati mankhwalawo mukugwiritsa ntchito osati chifukwa 
choti adokotala akuuza kutero kapena mulingo wake ndiwochulukirapo kuposa mmene amayenera kugwiritsidwira 
ntchito mukuyenera kundiuza.  Chinthu choti mundziwa ndichakuti angakhale m’kafukufukuyu akufunitsitsa kudziwa 
zam’mene mukugwiritsira ntchito mankhwala ozunguza bongo, khalani okhulupirira kuti chinsinsi chanu 
chisungidwa bwino lomwe. 
 
Choyenera kukumbukira musanayambe kufunsa mafunso: Perekani kadi yowenetsa ndondomeko yam’mene wodwala 
akuyenera kuyankhira mafunso kwa wodwala 
 
Funso loyamba (1) 
 
Kodi, m’moyo wanu mwagwiritsako ntchito mankhwala ozunguza bongo awa (pantchito 
zosakhudzana ndikudwala) 
Ayi Eya 
a. Fodya wosiyanasiyana   
b. Mowa wosiyanasiyana   
c. Chamba   
d. Kokeni   
e. Mankhwala ozunguza bongo wopumidwa monga guluwu, petulo   
f. Mankhwala ozunguza bongo wopatsa mphamvu monga ekistase ndi ena   
g. Mankhwala ogonetsa monga valiyamu   
h. Mankhwala ozunguza bongo wobwebwetetsa monga ketamini   
i. Mankhwala othetsa ululu ndinso ogonetsa monga herowini, mofini, codini   
j. Ena – tchulani dzina lake:   
Fufuzani bwino lomwe ngati wodwala wakanitsitsa kuti sanagwiritseko ntchito mankhwala ozunguza bongo: 
“angakhale nthawi imene munali pasukulu?” 
 
Ngati wodwala wayankha ayi kumankhwala onse, siyilani pomwe kumufunsa. 
Ngati wodwala wayankha eya kumankhwala ena aliwonse, funsani funso lachiwiri pamankhwala aliwonse amene 
anagwiritsidwapo ntchito 
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Funso lachiwiri (2) 
 
Kodi pamiyezi itatu yapitayi,  mwagwiritsa 
ntchito motani mankhwala ozunguza bongo 
munatchula aja? 
Ayi 
konse 
Kamodzi 
kapena 
kawiri 
Pamwezi 
kamodzi 
Pasabata 
kamodzi 
tsiku lililonse 
kapena pafupifupi 
tsiku lililonse 
a. Fodya wosiyanasiyana 0 
 
2 3 4 6 
b. Mowa wosiyanasiyana 0 2 3 4 6 
c. Chamba 0 2 3 4 6 
d. Kokeni 0 2 3 4 6 
e. Mankhwala ozunguza bongo 
wopumidwa monga guluwu, petulo 
0 2 3 4 6 
f. Mankhwala ozunguza bongo wopatsa 
mphamvu monga ekistase ndi ena 
0 2 3 4 6 
g. Mankhwala ogonetsa monga valiyamu 0 2 3 4 6 
h. Mankhwala ozunguza bongo 
wobwebwetetsa monga ketamini 
0 2 3 4 6 
i. Mankhwala othetsa ululu ndinso 
ogonetsa monga herowini, mofini, codini 
0 2 3 4 6 
j. Ena – tchulani dzina lake: 0 2 3 4 6 
 
Ngati sigwiritsa ntchito konse panopa mukafunsa funso lachiwiri, pitani kufunso lachisanu ndi chimodzi (6) 
Ngati alipo mankhwala amene anagwiritsidwa ntchito miyezi itatu yapitayi, pitilizani kufunsa funso lachitatu, 
lachinayi ndi lachisanu kwa mankhwala onse anagwiritsidwa ntchito. 
 
 
 
Funso lachitatu (3) 
 
Kodi pamiyezi itatu yapitayi,  mwakhala ndi 
chibaba chachikulu chofuna kugwiritsa 
ntchito mankhwala ozunguza bongo 
munatchula aja? 
Ayi 
konse 
Kamodzi 
kapena 
kawiri 
Pamwezi 
kamodzi 
Pasabata 
kamodzi 
tsiku lililonse 
kapena pafupifupi 
tsiku lililonse 
a. Fodya wosiyanasiyana 0 
 
3 4 5 6 
b. Mowa wosiyanasiyana 0 3 4 5 6 
c. Chamba 0 3 4 5 6 
d. Kokeni 0 3 4 5 6 
e. Mankhwala ozunguza bongo 
wopumidwa monga guluwu, petulo 
0 3 4 5 6 
f. Mankhwala ozunguza bongo wopatsa 
mphamvu monga ekistase ndi ena 
0 3 4 5 6 
g. Mankhwala ogonetsa monga valiyamu 0 3 4 5 6 
h. Mankhwala ozunguza bongo 
wobwebwetetsa monga ketamini 
0 3 4 5 6 
i. Mankhwala othetsa ululu ndinso 
ogonetsa monga herowini, mofini, codini 
0 3 4 5 6 
j. Ena – tchulani dzina lake: 0 3 4 5 6 
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Funso lachinayi (4) 
 
Kodi pamiyezi itatu yapitayi, ndikangati 
magwiritsadwe  ntchito amankhwala 
ozunguza bongo munatchula aja akhala 
akukupezetsani mavuto aumoyo wathupi, 
moyo wakhala pagulu ndi anthu ena, 
kuphwanya malamulo kapena mavuto 
achuma? 
Ayi 
konse 
Kamodzi 
kapena 
kawiri 
Pamwezi 
kamodzi 
Pasabata 
kamodzi 
tsiku lililonse 
kapena pafupifupi 
tsiku lililonse 
a. Fodya wosiyanasiyana 0 
 
4 5 6 7 
b. Mowa wosiyanasiyana 0 4 5 6 7 
c. Chamba 0 4 5 6 7 
d. Kokeni 0 4 5 6 7 
e. Mankhwala ozunguza bongo 
wopumidwa monga guluwu, petulo 
0 4 5 6 7 
f. Mankhwala ozunguza bongo wopatsa 
mphamvu monga ekistase ndi ena 
0 4 5 6 7 
g. Mankhwala ogonetsa monga valiyamu 0 4 5 6 7 
h. Mankhwala ozunguza bongo 
wobwebwetetsa monga ketamini 
0 4 5 6 7 
i. Mankhwala othetsa ululu ndinso 
ogonetsa monga herowini, mofini, codini 
0 4 5 6 7 
j. Ena – tchulani dzina lake: 0 4 5 6 7 
 
 
Funso lachisanu (5) 
 
Kodi pamiyezi itatu yapitayi,  ndikangati 
mwakhala mukukanika kupanga zinthu 
zimene mumayenera kuchita chifukwa 
chakugwiritsa ntchito mankhwala ozunguza 
bongo munatchula aja? 
Ayi 
konse 
Kamodzi 
kapena 
kawiri 
Pamwezi 
kamodzi 
Pasabata 
kamodzi 
tsiku lililonse 
kapena pafupifupi 
tsiku lililonse 
a. Fodya wosiyanasiyana 0 
 
5 6 7 8 
b. Mowa wosiyanasiyana 0 5 6 7 8 
c. Chamba 0 5 6 7 8 
d. Kokeni 0 5 6 7 8 
e. Mankhwala ozunguza bongo 
wopumidwa monga guluwu, petulo 
0 5 6 7 8 
f. Mankhwala ozunguza bongo wopatsa 
mphamvu monga ekistase ndi ena 
0 5 6 7 8 
g. Mankhwala ogonetsa monga valiyamu 0 5 6 7 8 
h. Mankhwala ozunguza bongo 
wobwebwetetsa monga ketamini 
0 5 6 7 8 
i. Mankhwala othetsa ululu ndinso 
ogonetsa monga herowini, mofini, codini 
0 5 6  8 
j. Ena – tchulani dzina lake: 0 5 6 7 8 
 
Funsani funso lachisanu  ndi chimodzi ndi chisani ndi chiwiri kukhudza mankhwala onse amene wodwala 
anagwiritsapo ntchito (onse amene anatchulidwa kuti anagwiritsidwapo ntchito pafunso loyamba lija) 
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Funso lachisanu  ndi chimodzi (6) 
 
Kodi alipo mzanu kaepna wachibale kapena munthu wina 
aliyense anaonetsa kukhudzika ndim’mene mwakhala 
mukugwiritsa ntchito mankhwala ozunguza bongo munatchula 
aja? 
Ayi 
konse 
Eya, 
pamiyezi 
itatu yapitayi 
Eya, koma osati 
pamiyezi itatu 
yapitayi 
a. Fodya wosiyanasiyana 0 
 
6 3 
b. Mowa wosiyanasiyana 0 6 3 
c. Chamba 0 6 3 
d. Kokeni 0 6 3 
e. Mankhwala ozunguza bongo wopumidwa monga guluwu, 
petulo 
0 6 3 
f. Mankhwala ozunguza bongo wopatsa mphamvu monga 
ekistase ndi ena 
0 6 3 
g. Mankhwala ogonetsa monga valiyamu 0 6 3 
h. Mankhwala ozunguza bongo wobwebwetetsa monga 
ketamini 
0 6 3 
i. Mankhwala othetsa ululu ndinso ogonetsa monga 
herowini, mofini, codini 
0 6 3 
j. Ena – tchulani dzina lake: 0 6 3 
 
 
Funso lachisani  ndi chiwiri (7) 
 
Kodi ilipo nthawi imene munayeserako ndikukanika  
kuchepetsa, kapena kusiya kugwiritsa ntchito mankhwala 
ozunguza bongo munatchula aja? 
Ayi 
konse 
Eya, 
pamiyezi 
itatu 
yapitayi 
Eya, koma osati 
pamiyezi itatu 
yapitayi 
a. Fodya wosiyanasiyana 0 
 
6 3 
b. Mowa wosiyanasiyana 0 6 3 
c. Chamba 0 6 3 
d. Kokeni 0 6 3 
e. Mankhwala ozunguza bongo wopumidwa monga guluwu, 
petulo 
0 6 3 
f. Mankhwala ozunguza bongo wopatsa mphamvu monga 
ekistase ndi ena 
0 6 3 
g. Mankhwala ogonetsa monga valiyamu 0 6 3 
h. Mankhwala ozunguza bongo wobwebwetetsa monga 
ketamini 
0 6 3 
i. Mankhwala othetsa ululu ndinso ogonetsa monga herowini, 
mofini, codini 
0 6 3 
j. Ena – tchulani dzina lake: 0 6 3 
 
Funso lachisanu ndi chitatu (8) 
 
 
 
 
Ayi 
konse 
Eya, 
pamiyezi 
itatu 
yapitayi 
Eya, koma 
osati pamiyezi 
itatu yapitayi 
 
Kodi munagwiritsako ntchito mankhwala ozunguza bongo 
pazibaya jekeseni? (osakhudzana ndi nkhani zachipatala) 
 
 
0 
 
2 
 
1 
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WHO ASSIST V3.1 RESPONSE CARD FOR PATIENTS 
 
Response Card – Substances – Chichewa Version 
 
Fodya wosiyanasiyana 
 
Mowa wosiyanasiyana 
 
Chamba 
 
Kokeni 
 
Mankhwala ozunguza bongo wopumidwa monga guluwu, petulo 
 
Mankhwala ozunguza bongo wopatsa mphamvu monga ekistase ndi ena 
 
Mankhwala ogonetsa monga valiyamu 
 
Mankhwala ozunguza bongo wobwebwetetsa monga ketamine 
 
Mankhwala othetsa ululu ndinso ogonetsa monga herowini, mofini, codini 
 
Ena – tchulani dzina lake: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Khadi ya mayankho kumafunso nambala 2 mpaka 5 
Ayi konse: ayi, sindinagwiritse ntchito pamiyezi itatu yapitayi  
Kamodzi kapena kawiri: kamodzi kapena kawiri pamiyezi itatu yapitayi  
Pamwezi kamodzi: kamodzi kapena katatu pamwezi  
Pasabata kamodzi: kamodzi kapena kanayi pasabata  
Tsiku lililonse kapena pafupifupi tsiku lililonse: masiku asanu kapena asanu ndi awiri 
Khadi ya mayankho kumafunso nambala 6 mpaka 8 
Ayi konse   
Eya, koma osati pamiyezi itatu yapitayi  
Eya, pamiyezi itatu yapitayi  
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ALCOHOL, SMOKING AND SUBSTANCE INVOLVEMENT SCREENING TEST (WHO ASSIST V3.1) 
FEEDBACK REPORT CARD FOR PATIENTS – Chichewa Version 
Dzina: ________________________________ Tsiku:  _____________________ 
 
 
Substance Score           Risk level 
a. Fodya wosiyanasiyana  0-3            Low 
4-26         Moderate 
27+           High 
b. Mowa wosiyanasiyana  0-10          Low 
11-26        Moderate 
27+           High 
c. Chamba  0-3            Low 
4-26         Moderate 
27+           High 
d. Kokeni  0-3            Low 
4-26         Moderate 
27+           High 
e. Mankhwala ozunguza bongo wopumidwa monga guluwu, 
petulo 
 0-3            Low 
4-26         Moderate 
27+           High 
f. Mankhwala ozunguza bongo wopatsa mphamvu monga 
ekistase ndi ena 
 0-3            Low 
4-26         Moderate 
27+           High 
g. Mankhwala ogonetsa monga valiyamu  0-3            Low 
4-26         Moderate 
27+           High 
h. Mankhwala ozunguza bongo wobwebwetetsa monga 
ketamini 
 0-3            Low 
4-26         Moderate 
27+           High 
i. Mankhwala othetsa ululu ndinso ogonetsa monga 
herowini, mofini, codini 
 0-3            Low 
4-26         Moderate 
27+           High 
j. Ena – tchulani dzina lake:  0-3            Low 
4-26         Moderate 
27+           High 
 
 
 
 
 
 
 
 
 
 
    
 
Kodi chiwerengero chokhudzana ndi mankhwala ozunguza bongo chimene chikutanthauza chiyani?  
 
Chiwopsyezo chotiska: chiopsyezo chanu ndichochepa kuti mukhala ndi mavuto ndi thanzi lanu komanso 
mavuto ena chifukwa cham’mene mukugwiritsira mankhwala ozunguza   
 
Chiwopsyezo chomvererako: muli pachiopsyezo chokhala ndi mavuto ndi thanzi lanu komanso mavuto 
ena chifukwa cham’mene mukugwiritsira mankhwala ozunguza  
 
Chiopsyezo chachikulu: muli pachiopsyezo chachikulu chokhala ndi mavuto akulu pa moyo wanu 
wam’thupi, ubale ndi anthu ena, chuma, kuswa malamulo adziko, ngati mupitiliza kugwiritsa ntchito 
mankhwala ozunguza bongo m’mene mukuchitira panopo.  
